Kawasaki Medical School
General Internal Medicine 4

川崎医科大学 総合内科学4(腫瘍内科学)
川崎医科大学総合医療センター 腫瘍内科

Prof's BlogFacebook

Kawasaki Medical School
General Internal Medicine 4

川崎医科大学 総合内科学4(腫瘍内科学)
川崎医科大学総合医療センター 腫瘍内科

Prof's BlogFacebook
External Link

新着情報

What's New!!

スタッフページ更新しました。

スタッフ紹介を更新しました。

Facebookページ開設しました。


HPとも連動していく予定です。こちらからどうぞ。

研究・業績ページを追加

これまでの主な研究業績について追加しました。

HP renewal!!

HPを全面的にリニューアルしました。

腫瘍センター開設

2014年12月から新たに腫瘍センターとして西4階病棟を開設しました。より専門性を高めた医療と看護を提供出来る体制が整いました。

新着情報

What's New!!

スタッフページ更新しました。

スタッフ紹介を更新しました。

Facebookページ開設しました。


HPとも連動していく予定です。
こちらからどうぞ。

更新中
About Us

講座概要

About Us

川崎医科大学 総合内科学4

総合内科学4(腫瘍内科学)教室は、肺がんをはじめとする様々な悪性腫瘍の診断・治療を、化学療法・分子標的治療の専門医が幅広い臓器に渡り担当しています。近年の画像診断技術の進歩により、ごく初期の肺がんなども比較的早期に発見できるようになっており、早期発見が治癒に結びつくことが期待できます。

一方、初診時に遠隔転移のある進行がんの場合も、新しい抗がん剤や分子標的薬、そして支持療法(吐き気止めや鎮痛剤など)の進歩により、たとえ抗がん剤治療を受けながらでもより良い生活を長く続けられるようになってきました。近年では外来通院での化学療法が進んでおり、仕事や家事をこれまで通り続けながらがん治療が受けられる方も増えています。当院の外来化学療法室は2011年4月から新たにスタートを切りましたがすでに多くの患者様が入院治療から外来治療へと移行されています。

川崎医科大学 総合内科学4

総合内科学4(腫瘍内科学)教室は、肺がんをはじめとする様々な悪性腫瘍の診断・治療を、化学療法・分子標的治療の専門医が幅広い臓器に渡り担当しています。近年の画像診断技術の進歩により、ごく初期の肺がんなども比較的早期に発見できるようになっており、早期発見が治癒に結びつくことが期待できます。

一方、初診時に遠隔転移のある進行がんの場合も、新しい抗がん剤や分子標的薬、そして支持療法(吐き気止めや鎮痛剤など)の進歩により、たとえ抗がん剤治療を受けながらでもより良い生活を長く続けられるようになってきました。近年では外来通院での化学療法が進んでおり、仕事や家事をこれまで通り続けながらがん治療が受けられる方も増えています。当院の外来化学療法室は2011年4月から新たにスタートを切りましたがすでに多くの患者様が入院治療から外来治療へと移行されています。

手術不能の肺がんに限らず、大腸がん、胃がん、乳がん、卵巣がん、リンパ腫なども同様に、腫瘍内科医としてその診療を行っています。小回りの利く診療体制で素早く診断・治療を行う腫瘍内科ですので、悪性腫瘍についてお困りの患者様は、ぜひ一度ご相談ください。

Cytotoxic agents

Molecular target

Radiation therapy

Palliative care

Cytotoxic agents

Molecular target

Radiation therapy

Palliative care

Chemoroom

外来化学療法

For patients treated in outpatient setting

外来化学療法室について

当院では2010年12月から外来化学療法室を新設し、それまで内科外来などで他の一般外来患者様の点滴と同じ処置室で行われていた抗がん剤点滴を、化学療法を受けられる患者様専用の落ち着いた空間で受けられるようになりました。また、専任看護師が常時在室することにより、抗がん剤治療を受けられる患者様が安心して治療を受けられるようになっています。

実績

現在、一か月あたりのべ70人の患者様が外来化学療法で抗がん剤治療を受けられており、抗がん剤治療を受けながらそれまでの生活や仕事を続けられています。 近年の抗がん剤の進歩、支持療法(副作用を抑える治療など)の発達によりそれまで入院主体で行われていた多くの抗がん剤治療が必ずしも入院を必要としなくなり、外来でも安全に行うことが出来るようになりました。当科では、個々の患者様のニーズに沿って広く治療選択肢を提示させていただいており、多くの患者様が入院での抗がん剤治療から外来通院での抗がん剤治療へ移行されております。

患者様の安心のために

また毎日、翌日の外来化学療法室で抗がん剤治療を受けられる患者様について、複数の腫瘍内科医師・看護師・薬剤師が共同してカンファレンスを行い、抗がん剤の種類や量、薬剤の組み合わせが適切か、副作用がみられていないかなどを検討し、個々の患者様の治療担当医に適宜フィードバックを行い、ダブルチェックをすることでより安全に安心して治療が受けられるように日々努力しています。

外来化学療法は今後さらに発展が予想されており、抗がん剤治療を受けられる患者様の意思やQOL(Quality of life;生活の質)を重視した治療を実現していくものと考えています。

Need more Information? Please contact us.

外来化学療法

For patients treated in outpatient setting

外来化学療法室について

当院では2010年12月から外来化学療法室を新設し、それまで内科外来などで他の一般外来患者様の点滴と同じ処置室で行われていた抗がん剤点滴を、化学療法を受けられる患者様専用の落ち着いた空間で受けられるようになりました。また、専任看護師が常時在室することにより、抗がん剤治療を受けられる患者様が安心して治療を受けられるようになっています。

実績

現在、一か月あたりのべ70人の患者様が外来化学療法で抗がん剤治療を受けられており、抗がん剤治療を受けながらそれまでの生活や仕事を続けられています。 近年の抗がん剤の進歩、支持療法(副作用を抑える治療など)の発達によりそれまで入院主体で行われていた多くの抗がん剤治療が必ずしも入院を必要としなくなり、外来でも安全に行うことが出来るようになりました。当科では、個々の患者様のニーズに沿って広く治療選択肢を提示させていただいており、多くの患者様が入院での抗がん剤治療から外来通院での抗がん剤治療へ移行されております。

患者様の安心のために

また毎日、翌日の外来化学療法室で抗がん剤治療を受けられる患者様について、複数の腫瘍内科医師・看護師・薬剤師が共同してカンファレンスを行い、抗がん剤の種類や量、薬剤の組み合わせが適切か、副作用がみられていないかなどを検討し、個々の患者様の治療担当医に適宜フィードバックを行い、ダブルチェックをすることでより安全に安心して治療が受けられるように日々努力しています。

外来化学療法は今後さらに発展が予想されており、抗がん剤治療を受けられる患者様の意思やQOL(Quality of life;生活の質)を重視した治療を実現していくものと考えています。

Need more Information? Please contact us.
Professor's comments

教授挨拶

Professor's comment

川崎医科大学 総合内科学4
教授 
瀧川 奈義夫

Prof's Blog

川崎医科大学附属川崎病院 総合内科学4教室のホームページにおいでいただき、誠にありがとうございます。
当院は、平成23年4月に学校法人川崎学園の運営する施設として、また川崎医科大学の第2の附属病院として新たな出発をしました。岡山市の中核病院として安全・安心な医療を提供し、患者さんならびに地域医療機関から信頼されている病院です。総合内科学教室は4つありますが、いずれも各分野の高い専門性を保ちながら、各疾患の初期治療とcommon diseaseの診療を行っています。私たちの教室は腫瘍内科として、肺がんを中心としたあらゆる進行悪性腫瘍(消化器がん、乳がん、卵巣がん、頭頸部がん、腎がん、原発不明がん、胚細胞腫瘍、リンパ腫、肉腫など)の診療を担当しています。がん化学療法および緩和医療に精通した医師が、協調性をもってチーム医療を推進しています。

研究面では二つの柱(基礎研究と臨床研究)を両立しています。文部科学省研究費として、「非喫煙者肺癌モデルを用いた細気管支肺胞上皮癌より浸潤癌への進展機構の解明(代表)」、「遺伝子改変マウスを利用したEGFR遺伝子変異陽性肺癌の基礎的臨床的検討(分担)」「含鉄蛋白質による悪性中皮腫動物モデルの発癌機構の解明(分担)」を獲得し、平成24年の米国癌学会には3演題が採用されました。臨床研究では、岡山肺癌治療研究会(OLCSG)および消化器がんを中心とした中四国がん臨床試験グループ(JSWOG)の一員として、活動を行っています。

私たちの教室は、

「cure and care for the patient’s smile」

を合言葉に、進行がんと闘っています。かなり手ごわい相手ですが、患者さんの笑顔のために、優しくかつ力強く医療を行っていますので、今後ともよろしくお願い申し上げます。


総合内科学4 教授 瀧川奈義夫
2012年3月吉日

教授挨拶

Professor's comment

川崎医科大学 総合内科学4
教授 
瀧川 奈義夫

Prof's Blog

川崎医科大学総合医療センター 総合内科学4教室のホームページにおいでいただき、誠にありがとうございます。
当院は、平成23年4月に学校法人川崎学園の運営する施設として、また川崎医科大学の第2の附属病院として新たな出発をしました。岡山市の中核病院として安全・安心な医療を提供し、患者さんならびに地域医療機関から信頼されている病院です。総合内科学教室は4つありますが、いずれも各分野の高い専門性を保ちながら、各疾患の初期治療とcommon diseaseの診療を行っています。私たちの教室は腫瘍内科として、肺がんを中心としたあらゆる進行悪性腫瘍(消化器がん、乳がん、卵巣がん、頭頸部がん、腎がん、原発不明がん、胚細胞腫瘍、リンパ腫、肉腫など)の診療を担当しています。がん化学療法および緩和医療に精通した医師が、協調性をもってチーム医療を推進しています。

研究面では二つの柱(基礎研究と臨床研究)を両立しています。文部科学省研究費として、「非喫煙者肺癌モデルを用いた細気管支肺胞上皮癌より浸潤癌への進展機構の解明(代表)」、「遺伝子改変マウスを利用したEGFR遺伝子変異陽性肺癌の基礎的臨床的検討(分担)」「含鉄蛋白質による悪性中皮腫動物モデルの発癌機構の解明(分担)」を獲得し、平成24年の米国癌学会には3演題が採用されました。臨床研究では、岡山肺癌治療研究会(OLCSG)および消化器がんを中心とした中四国がん臨床試験グループ(JSWOG)の一員として、活動を行っています。

私たちの教室は、

「cure and care for the patient’s smile」

を合言葉に、進行がんと闘っています。かなり手ごわい相手ですが、患者さんの笑顔のために、優しくかつ力強く医療を行っていますので、今後ともよろしくお願い申し上げます。


総合内科学4 教授 瀧川奈義夫
2012年3月吉日
STAFF

スタッフ紹介

STAFF

教授
瀧川 奈義夫

Nagio Takigawa

Prof's Blog

教授
瀧川 奈義夫

Nagio Takigawa

Prof's Blog

略歴

昭和63年3月 岡山大学医学部医学科卒業
平成4年3月 岡山大学大学院医学研究科博士課程(内科学)終了
平成4年5月 国立療養所山陽荘病院 内科(現 山口宇部医療センター)
平成6年12月 国立病院四国がんセンター 内科(現 四国がんセンター)
平成12年4月 岡山大学医学部附属病院 第2内科
平成12年10月 Cleveland Clinic Foundation, Cancer Center
平成14年10月 国立療養所南岡山病院 呼吸器科(現 南岡山医療センター)
平成17年5月 岡山大学大学院医歯薬学総合研究科 血液・腫瘍・呼吸器内科学
平成17年7月 岡山大学医学部歯学部附属病院 呼吸器内科
平成20年6月 岡山大学病院 呼吸器・アレルギー内科
平成23年4月 川崎医科大学 総合内科学4 教授

略歴

昭和63年3月 岡山大学医学部医学科卒業
平成4年3月 岡山大学大学院医学研究科博士課程(内科学)終了
平成4年5月 国立療養所山陽荘病院 内科(現 山口宇部医療センター)
平成6年12月 国立病院四国がんセンター 内科(現 四国がんセンター)
平成12年4月 岡山大学医学部附属病院 第2内科
平成12年10月 Cleveland Clinic Foundation, Cancer Center
平成14年10月 国立療養所南岡山病院 呼吸器科(現 南岡山医療センター)
平成17年5月 岡山大学大学院医歯薬学総合研究科 血液・腫瘍・呼吸器内科学
平成17年7月 岡山大学医学部歯学部附属病院 呼吸器内科
平成20年6月 岡山大学病院 呼吸器・アレルギー内科
平成23年4月 川崎医科大学 総合内科学4 教授

所属学会

日本内科学会(中国支部評議員)、日本癌学会、日本癌治療学会、日本肺癌学会(評議員)、日本呼吸器学会(代議員)、日本呼吸器内視鏡学会(評議員)、日本臨床腫瘍学会(評議員)、米国癌学会

専門分野

内科一般、腫瘍全般・呼吸器疾患

資格等

日本内科学会認定医・総合内科専門医・指導医
日本呼吸器内視鏡学会専門医・指導医
日本癌治療認定機構認定がん治療認定医
日本臨床腫瘍学会がん薬物療法専門医・指導医
他多数

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.
1. Yin Y, Ochi N, Craven TW, Baker D, Takigawa N, Suga H. De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor. J Am Chem Soc. 2019 Dec 11;141(49):19193–7.

2. Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, et al. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig. 2019 Nov;57(6):512–33.

3. Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 04;393(10183):1819–30.

4. Kawahara T, Ochi N, Kato K, Shibamoto K, Nagasaki Y, Nakagawa N, et al. Wandering consolidation. Thorax. 2019 Aug;74(8):821–2.

5. Higo H, Kubo T, Makimoto S, Makimoto G, Ihara H, Masaoka Y, et al. Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Jpn J Clin Oncol. 2019 May 1;49(5):458–64.

6. Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, et al. A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. Asia Pac J Clin Oncol. 2019 Aug;15(4):250–6.

1. Yoshida M, Yokota E, Sakuma T, Yamatsuji T, Takigawa N, Ushijima T, et al. Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma. Oncotarget. 2018 Jun 26;9(49):29220–32.

2. Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, et al. Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17. Ther Clin Risk Manag. 2018;14:1457–65.

3. Yamane H, Nishie H, Ochi N, Yamagishi T, Nakagawa N, Nagasaki Y, et al. “Engagement ring” image conveys regrettable outcome for aged patients with non-small cell lung cancer. Thorac Cancer. 2018;9(7):897–8.

4. Yamane H, Kunisada T, Ozaki T, Ochi N, Honda Y, Nagasaki Y, et al. Patients with osteosarcoma and soft tissue sarcoma might become “cancer refugees” in some Japanese regional cities. Cancer Manag Res. 2018;10:353–9.

5. Takigawa N, Ochi N, Yamane H. Histology versus cytology: PD-L1 testing in non-small cell lung cancer. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S225–7.

6. Takigawa N, Ochi N, Yamane H. Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S352–5.

7. Takigawa N. How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer? J Thorac Oncol. 2018;13(10):1438–40.

8. Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, et al. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemother Pharmacol. 2018;82(6):1031–8.

9. Ochi N, Yamane H, Honda Y, Takigawa N. Accidental aspiration of denture cleanser tablets caused severe mucosal edema in upper airway. Clin Respir J. 2018 Jan;12(1):291–4.

10. Ochi N, Wakabayashi T, Urakami A, Yamatsuji T, Ikemoto N, Nagasaki Y, et al. Descending necrotizing mediastinitis in a healthy young adult. Ther Clin Risk Manag. 2018;14:2013–7.

11. Ochi N, Takahashi K, Yamane H, Takigawa N. Acute necrotizing encephalopathy in an adult with influenza A infection. Ther Clin Risk Manag. 2018;14:753–6.

12. Ochi N, Kawahara T, Yamane H, Takigawa N. Erythema as a Visual Surrogate Marker of Glucagonoma. Intern Med. 2018 Aug 1;57(15):2283–4.

13. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018 Nov 1;48(11):995–1000.

14. Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, et al. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Lung Cancer. 2018;115:103–8.

15. Nakagawa N, Ochi N, Yamane H, Honda Y, Nagasaki Y, Urata N, et al. Ceftriaxone-associated pancreatitis captured on serial computed tomography scans. Radiol Case Rep. 2018 Feb;13(1):43–6.

16. Minami D, Takigawa N, Oki M, Saka H, Shibayama T, Kiura K. Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation. Respir Investig. 2018 Jul;56(4):356–60.

17. Makimoto G, Kubo T, Oze I, Ohashi K, Hotta K, Tabata M, et al. Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. Jpn J Clin Oncol. 2018 Mar 1;48(3):287–90.

1. Yokota E, Yamatsuji T, Takaoka M, Haisa M, Takigawa N, Miyake N, et al. Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma. Oncotarget. 2017 Nov 28;8(61):103063–76.

2. Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, et al. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clin Lung Cancer. 2017;18(2):241–4.

3. Minami D, Takigawa N, Kano H, Ninomiya T, Kubo T, Ichihara E, et al. Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. Jpn J Clin Oncol. 2017 May 1;47(5):434–7.

4. Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, et al. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer. 2017;112:188–94.

5. Hosokawa S, Bessho A, Harada D, Kouzuki T, Hotta K, Sone N, et al. Phase I/II trial of weekly nab-Paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations (OLCSG1303). Ann Oncol. 2017 Oct;28 Suppl 9:ix83.

6. Honda Y, Takigawa N, Ichihara E, Ninomiya T, Kubo T, Ochi N, et al. Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells. Acta Med Okayama. 2017;71(6):505–12.

7. Yamane H, Ochi N, Honda Y, Takigawa N. Gynecomastia as a Paraneoplastic Symptom of Choriocarcinoma. Intern Med. 2016;55(18):2739–40.

8. Yamane H, Monobe Y, Tanikawa T, Ochi N, Honda Y, Kawamoto H, et al. Herpetic esophagitis following bendamustine-containing regimen. Ther Clin Risk Manag. 2016;12:883–6.

9. Osawa M, Ohashi K, Kubo T, Ichihara E, Takata S, Takigawa N, et al. Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation. Acta Med Okayama. 2016 Aug;70(4):243–53.

10. Oda N, Hotta K, Yoshioka H, Kudo K, Ichihara E, Kato Y, et al. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol. 2016 Nov;78(5):941–7.

11. Ochi N, Yamane H, Honda Y, Takigawa N. Dropped Head Syndrome Following Mantle Radiation Therapy. Intern Med. 2016;55(4):421–2.

12. Ochi N, Kawamoto H, Monobe Y, Takigawa N. Cytomegalovirus Colitis in a Lung Cancer Patient. Intern Med. 2016;55(16):2313–4.

13. Ochi N, Isozaki H, Takeyama M, Singer JW, Yamane H, Honda Y, et al. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. Exp Cell Res. 2016 10;344(2):194–200.

14. Nagasaki Y, Yamane H, Ochi N, Honda Y, Takigawa N. High Uptake of FDG Along a Biliary Stent. Clin Nucl Med. 2016 Nov;41(11):890–1.

15. Minami D, Takigawa N, Watanabe H, Ninomiya T, Kubo T, Ohashi K, et al. Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. Jpn J Clin Oncol. 2016 Sep;46(9):871–4.

16. Minami D, Takigawa N, Oda N, Ninomiya T, Kubo T, Ohashi K, et al. Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Jpn J Clin Oncol. 2016 Jun;46(6):529–33.

17. Kudo K, Hotta K, Bessho A, Nogami N, Kozuki T, Kuyama S, et al. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol. 2016;77(5):1005–9.

18. Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, et al. A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Cancer Chemother Pharmacol. 2016 Oct;78(4):769–74.

19. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1–222.

20. Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, et al. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Res. 2016 Mar 15;76(6):1506–16.

21. Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, et al. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Clin Lung Cancer. 2016;17(6):602–5.

22. Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, et al. Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. Clin Lung Cancer. 2016 Jan;17(1):75–9.

23. Fukazawa T, Guo M, Ishida N, Yamatsuji T, Takaoka M, Yokota E, et al. SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. Sci Rep. 2016 Feb 5;6:20113.

24. Yamane H, Ochi N, Yamagishi T, Takigawa N, Maeda Y. Progressive paraplegia caused by recurrence of mantle-cell lymphoma with atypical spinal magnetic resonance imaging features. J Cancer Res Ther. 2015 Dec;11(4):1036.

25. Yamane H, Ochi N, Yamagishi T, Honda Y, Takeyama M, Takigawa N. Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study. Ther Clin Risk Manag. 2015;11:949–59.

26. Yamane H, Ochi N, Honda Y, Takigawa N. PET Superscan Caused by Lung Cancer. Intern Med. 2015;54(22):2951.

27. Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, et al. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Am J Cancer Res. 2015;5(4):1553–7.

28. Yamane H, Fukuda N, Nishino K, Yoshida K, Ochi N, Yamagishi T, et al. Non-occlusive mesenteric ischemia after splenic metastasectomy for small-cell lung cancer. Intern Med. 2015;54(7):743–7.

29. Yamagishi T, Ochi N, Yamane H, Kuribayashi F, Takigawa N. A 60-year-old asymptomatic woman with pulmonary lesions and cervical lymphadenopathy. Chest. 2015 Feb;147(2):e48–51.

30. Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, et al. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Lung Cancer. 2015 Feb;87(2):141–7.

31. Minami D, Takigawa N, Morichika D, Kubo T, Ohashi K, Sato A, et al. Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung cancer. Respir Investig. 2015 May;53(3):93–7.

32. Minami D, Takigawa N, Kato Y, Kudo K, Isozaki H, Hashida S, et al. Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. Cancer Sci. 2015 Oct;106(10):1296–302.

33. Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, et al. Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemother Pharmacol. 2015 Aug;76(2):251–6.

34. Isozaki H, Takigawa N, Kiura K. Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers (Basel). 2015 Apr 30;7(2):763–83.

35. Isoda R, Yamane H, Nezuo S, Monobe Y, Ochi N, Honda Y, et al. Successful palliation for an aged patient with primary pericardial mesothelioma. World J Surg Oncol. 2015 Sep 17;13:273.

36. Ishida N, Fukazawa T, Maeda Y, Yamatsuji T, Kato K, Matsumoto K, et al. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. Exp Cell Res. 2015 Jul 15;335(2):197–206.

37. Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol. 2015 Mar;10(3):486–91.

38. Hotta K, Ninomiya K, Takigawa N, Tanimoto M, Kiura K. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol. 2015 Jun;45(6):603–4.

39. Hotta K, Kato Y, Leighl N, Takigawa N, Gaafar RM, Kayatani H, et al. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. PLoS ONE. 2015;10(3):e0121211.

40. Yasugi M, Takigawa N, Ochi N, Ohashi K, Harada D, Ninomiya T, et al. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. Exp Cell Res. 2014 Aug 15;326(2):201–9.

41. Yamane H, Ochi N, Yamagishi T, Takigawa N. Guidelines for long-term steroid therapy in end-of-life palliative care. J Clin Oncol. 2014 Feb 20;32(6):607–8.

42. Yamane H, Ochi N, Yamagishi T, Takigawa N. Fibrin sheath following pleurodesis. BMJ Case Rep. 2014 Jan 31;2014.

43. Yamane H, Ochi N, Isozaki H, Yamagishi T, Honda Y, Takigawa N. Skin involvement in diffuse large B-cell lymphoma detected using positron emission tomography. Thorac Cancer. 2014 Nov;5(6):581–2.

44. Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst. 2014 Jan;106(1):djt338.

45. Yamagishi T, Shimizu K, Ochi N, Yamane H, Irei I, Sadahira Y, et al. Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between “squamous” and “non-squamous” cell carcinoma. Diagn Pathol. 2014 May 29;9:103.

46. Yamagishi T, Ochi N, Yamane H, Takigawa N. Neurogenic pulmonary edema after subarachnoid hemorrhage. J Emerg Med. 2014 May;46(5):683–4.

47. Yamagishi T, Ochi N, Yamane H, Hasebe S, Takigawa N. Epiphora in lung cancer patients receiving docetaxel: a case series. BMC Res Notes. 2014 May 30;7:322.

48. Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, et al. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 2014 Mar;37(2):84–92.

49. Ochi N, Yamane H, Hotta K, Fujii H, Isozaki H, Honda Y, et al. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Drug Des Devel Ther. 2014;8:2401–8.

50. Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, Hotta K, et al. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp Cell Res. 2014 Mar 10;322(1):168–77.

51. Ochi N, Goto D, Yamane H, Yamagishi T, Honda Y, Monobe Y, et al. Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma. Onco Targets Ther. 2014;7:1847–50.

52. Murakami T, Takigawa N, Ninomiya T, Ochi N, Yasugi M, Honda Y, et al. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer. 2014 Jan;83(1):30–6.

53. Minami D, Takigawa N, Inoue H, Hotta K, Tanimoto M, Kiura K. Rapid on-site evaluation with BIOEVALUATOR(®) during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases. Ann Thorac Med. 2014 Jan;9(1):14–7.

54. Kojima K, Kato K, Fukazawa T, Morita I, Takigawa N, Monobe Y, et al. A case of autoimmune pulmonary alveolar proteinosis appearing as a localized ground-glass opacity. Jpn J Radiol. 2014 Nov;32(11):657–60.

55. Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, et al. Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol. 2014 May;73(5):943–50.

56. Isozaki H, Yasugi M, Takigawa N, Hotta K, Ichihara E, Taniguchi A, et al. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. Jpn J Clin Oncol. 2014 Oct;44(10):963–8.

57. Hotta K, Kiura K, Tabata M, Takigawa N, Tanimoto M, Ueoka H. A survey of Japanese thoracic oncologists’ perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer. Chest. 2014 Dec;146(6):e222–5.

58. Harada D, Takigawa N, Kiura K. The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel). 2014 Mar 26;6(2):708–22.

59. Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, et al. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801. Eur J Cancer. 2014 Nov;50(16):2783–90.

60. Yamane H, Takigawa N. Thickened colon wall in follicular lymphoma. Int J Hematol. 2013 May;97(5):549–50.

61. Yamane H, Ochi N, Yasugi M, Tabayashi T, Yamagishi T, Monobe Y, et al. Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. Onco Targets Ther. 2013;6:155–60.

62. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013 Feb 15;319(4):417–23.

63. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013 May 15;73(10):3051–61.

64. Saito K, Takigawa N, Ohtani N, Iioka H, Tomita Y, Ueda R, et al. Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers. Mol Cancer Ther. 2013 Aug;12(8):1616–28.

65. Saeki T, Tokuda Y, Takigawa N, Tsurutani J. [Discussion about Biomilar development: Filgrastim BS injection and its applications in clinical practice]. Gan To Kagaku Ryoho. 2013 Oct;40(10):1365–76.

66. Ochi N, Yamane H, Yamagishi T, Monobe Y, Takigawa N. Methotrexate-induced lymphoproliferative disease: Epstein-Barr virus-associated lymphomatoid granulomatosis. J Clin Oncol. 2013 Jul 10;31(20):e348-350.

67. Ochi N, Yamane H, Yamagishi T, Takigawa N. Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases. Lung Cancer. 2013 Apr;80(1):111–3.

68. Ochi N, Yamane H, Yamagishi T, Takigawa N, Monobe Y. Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene? Lung Cancer. 2013 Jan;79(1):94–5.

69. Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013 May;12(5):589–97.

70. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2013 Feb;11(2):140–8.

71. Minami D, Takigawa N, Hayakawa H, Mizuta M, Kudo K, Uchida K, et al. Usefulness of endobronchial ultrasound-guided transbronchial needle aspiration in distinguishing sarcoidosis from recurrent cancer in patients with lymphadenopathy after surgery. Jpn J Clin Oncol. 2013 Nov;43(11):1110–4.

72. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, et al. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Sci. 2013 Jan;104(1):78–84.

73. Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, et al. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 2013 Sep;81(3):435–9.

74. Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol. 2013 Nov;43(11):1115–23.

75. Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013 Jan;79(1):20–6.

76. Hayakawa H, Ichihara E, Ohashi K, Ninomiya T, Yasugi M, Takata S, et al. Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. Cancer Sci. 2013 Nov;104(11):1440–6.

77. Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao X-H, et al. Inhibition of the growth factor MDK/midkine by a novel small molecule compound to treat non-small cell lung cancer. PLoS ONE. 2013;8(8):e71093.

78. Bao X-H, Takaoka M, Hao H-F, Fukazawa T, Yamatsuji T, Sakurama K, et al. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer. Oncol Rep. 2013 Jan;29(1):45–50.

79. Yamane H, Ohashi K, Suwaki T, Takigawa N. Ruptured littoral cell angiosarcoma causing hemoperitoneum. Intern Med. 2012;51(3):337–8.

80. Yamane H, Ochi N, Tabayashi T, Takigawa N. Stewart-Treves syndrome after cervical cancer. Intern Med. 2012;51(5):513.

81. Yamane H, Ochi N, Tabayashi T, Lu L, Yamagishi T, Monobe Y, et al. Elevated coagulation factor VIII plasma activity in a patient with lymphangiosarcoma. Intern Med. 2012;51(22):3213–5.

82. Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer. 2012 Jul;77(1):134–9.

83. Tsuchida T, Yamane H, Ochi N, Tabayashi T, Hiraki A, Nogami N, et al. Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancer. Anticancer Res. 2012 Mar;32(3):887–92.

84. Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012 May;14(5):565–9.

85. Tokuda Y, Takigawa N, Kozuki T, Kamei H, Bessho A, Tada A, et al. Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Acta Oncol. 2012 Apr;51(4):537–40.

86. Takata S, Takigawa N, Segawa Y, Kubo T, Ohashi K, Kozuki T, et al. STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer. 2012 Jan;75(1):24–9.

87. Ozaki S, Takigawa N, Ichihara E, Hotta K, Oze I, Kurimoto E, et al. Favorable response of heavily treated Wilms’ tumor to paclitaxel and carboplatin. Onkologie. 2012;35(5):283–6.

88. Okada T, Takigawa N, Kishino D, Katayama H, Kuyama S, Sato K, et al. Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice. Acta Med Okayama. 2012;66(3):245–51.

89. Ochi N, Yasugi M, Yamane H, Tabayashi T, Kawanaka N, Okimoto N, et al. Spontaneous expectoration of tumor tissue in a patient with adenocarcinoma of the lung. Respir Care. 2012 Sep;57(9):1521–3.

90. Ochi N, Yasugi M, Takigawa N. Asymptomatic double aortic arch with compressed oesophagus in an adult. BMJ Case Rep. 2012 Apr 2;2012.

91. Ochi N, Hotta K, Takigawa N, Oze I, Fujiwara Y, Ichihara E, et al. Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. PLoS ONE. 2012;7(8):e42798.

92. Nogami N, Hotta K, Segawa Y, Takigawa N, Hosokawa S, Oze I, et al. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402. Acta Oncol. 2012 Jul;51(6):768–73.

93. Kudo K, Ichihara E, Hisamoto A, Hotta K, Ichimura K, Tanimoto Y, et al. [Case report: Two cases of adult Langerhans cell histiocytosis treated with systemic chemotherapy]. Nippon Naika Gakkai Zasshi. 2012 May 10;101(5):1386–8.

94. Honda Y, Takigawa N, Fushimi S, Ochi N, Kubo T, Ozaki S, et al. Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors. Lung Cancer. 2012 Oct;78(1):121–4.

95. Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, et al. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci. 2012 Oct;103(10):1795–802.

96. Fujii M, Hotta K, Takigawa N, Hisamoto A, Ichihara E, Tabata M, et al. Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response. Lung Cancer. 2012 Oct;78(1):107–11.

97. Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci. 2012 Mar;103(3):510–4.

98. Zhang D, Takigawa N, Ochi N, Tanimoto Y, Noujima D, Chen YY, et al. Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung Cancer. 2011 Sep;73(3):379–80.

99. Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, et al. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett. 2011 Oct 28;309(2):228–35.

100. Yamane H, Ohsawa M, Shiote Y, Umemura S, Suwaki T, Shirakawa A, et al. Cavitary pulmonary involvement of diffuse large B-cell lymphoma transformed from extra nodal marginal zone B-cell lymphoma MALT type. Clin J Gastroenterol. 2011 Dec;4(6):401–6.

101. Yamane H, Matsubara M, Umemura S, Suwaki T, Kamei H, Takigawa N, et al. Variant angina pectoris associated with FOLFOX4 therapy. World J Gastrointest Oncol. 2011 Nov 15;3(11):165–8.

102. Yamane H, Kinugawa M, Umemura S, Shiote Y, Kudo K, Suwaki T, et al. An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. World J Clin Oncol. 2011 Jul 10;2(7):299–302.

103. Umemura S, Yamane H, Yano T, Hoshika T, Shiote Y, Takigawa N, et al. Synchronous double primary lung cancers with different response to pemetrexed. Anticancer Drugs. 2011 Jun;22(5):473–6.

104. Umemura S, Yamane H, Suwaki T, Katoh T, Yano T, Shiote Y, et al. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin Oncol. 2011 Oct;137(10):1469–75.

105. Taniguchi A, Takigawa N, Hotta K, Matsumura T, Tanimoto M, Kiura K. [A relapse of small-cell lung cancer ten years after concomitant chemoradiotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell transfusion]. Nihon Kokyuki Gakkai Zasshi. 2011 Sep;49(9):697–701.

106. Takigawa N, Kiura K, Segawa Y, Hotta K, Tamaoki A, Tokuda Y, et al. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007. J Thorac Oncol. 2011 Jun;6(6):1087–91.

107. Takigawa N, Kiura K, Kishimoto T. Medical treatment of mesothelioma: anything new? Curr Oncol Rep. 2011 Aug;13(4):265–71.

108. Takigawa N, Kiura K, Hotta K, Hosokawa S, Nogami N, Aoe K, et al. A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. Lung Cancer. 2011 Jan;71(1):60–4.

109. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011 Sep;10(9):1720–7.

110. Nogami N, Hotta K, Kuyama S, Kiura K, Takigawa N, Chikamori K, et al. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Lung Cancer. 2011 Oct;74(1):80–4.

111. Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer. 2011 Dec 15;129(12):2836–46.

112. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS ONE. 2011;6(11):e26646.

113. Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol. 2010 Jan;5(1):99–104.

114. Takahashi T, Sato K, Suzaki N, Goda Y, Takigawa N. [A case of severe bronchial mucosal injury caused by iron pill aspiration]. Nihon Kokyuki Gakkai Zasshi. 2010 Feb;48(2):123–7.

115. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010 Jul 10;28(20):3299–306.

116. Segawa Y, Kiura K, Hotta K, Takigawa N, Tabata M, Matsuo K, et al. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. J Thorac Oncol. 2010 Sep;5(9):1430–4.

117. Ochi N, Takigawa N, Yasugi M, Ishida E, Kawamoto H, Taniguchi A, et al. Obstructive jaundice at the initial presentation in small-cell lung cancer. Int Med Case Rep J. 2010;3:9–12.

118. Nojima D, Kiura K, Hotta K, Takigawa N, Tabata M, Tanimoto M. [Large cell neuroendocrine carcinoma of the mediastinum]. Nihon Kokyuki Gakkai Zasshi. 2010 Jul;48(7):506–10.

119. Hotta K, Kiura K, Takigawa N, Yoshioka H, Hayashi H, Fukuyama H, et al. Desire for information and involvement in treatment decisions: lung cancer patients’ preferences and their physicians’ perceptions: results from Okayama Lung Cancer Study Group Trial 0705. J Thorac Oncol. 2010 Oct;5(10):1668–72.

120. Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol. 2010 Feb;5(2):179–84.

121. Hotta K, Kiura K, Takigawa N, Suzuki E, Yoshioka H, Okada T, et al. Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung Cancer. 2010 Dec;70(3):308–12.

122. Fujimoto N, Kiura K, Takigawa N, Fujiwara Y, Toyooka S, Umemura S, et al. Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer. Acta Med Okayama. 2010 Feb;64(1):33–7.

123. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS ONE. 2009 Nov 13;4(11):e7835.

124. Ohashi K, Takigawa N, Osawa M, Ichihara E, Takeda H, Kubo T, et al. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res. 2009 Sep 1;69(17):7088–95.

125. Kubo T, Takigawa N, Kiura K, Nishida A, Ochi N, Kashihara H, et al. Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. Anticancer Res. 2009 Jul;29(7):2759–60.

126. Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer. 2009 Apr 15;124(8):1778–84.

127. Kishino D, Kiura K, Takigawa N, Katayama H, Kuyama S, Sato K, et al. Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. Lung Cancer. 2009 Sep;65(3):284–9.

128. Ichihara E, Ohashi K, Takigawa N, Osawa M, Ogino A, Tanimoto M, et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res. 2009 Jun 15;69(12):5091–8.

129. Hotta K, Kiura K, Takigawa N, Kuyama S, Segawa Y, Yonei T, et al. Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol. 2009 Jan;135(1):117–23.

130. Hotta K, Kiura K, Shirahige A, Takata S, Takigawa N, Tabata M, et al. A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization. Acta Oncol. 2009;48(3):471–3.

131. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009 Mar;4(3):311–7.

132. Hosokawa S, Toyooka S, Fujiwara Y, Tokumo M, Soh J, Takigawa N, et al. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer. 2009 Oct;66(1):107–13.

133. Hiraki T, Gobara H, Mimura H, Sano Y, Takigawa N, Tanaka T, et al. Aspergilloma in a cavity formed after percutaneous radiofrequency ablation for lung cancer. J Vasc Interv Radiol. 2009 Nov;20(11):1499–500.

134. Chikamori K, Kishino D, Takigawa N, Hotta K, Nogami N, Kamei H, et al. A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer. 2009 Jul;65(1):74–9.

135. Umemura S, Fujimoto N, Hiraki A, Gemba K, Takigawa N, Fujiwara K, et al. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Carcinogenesis. 2008 Sep;29(9):1845–9.

136. Takigawa N, Tanimoto M. [Vinca alkaloid and MDR1]. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086–9.

137. Kuyama S, Hotta K, Tabata M, Segawa Y, Fujiwara Y, Takigawa N, et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2008 May;3(5):477–82.

138. Ichihara E, Tabata M, Takigawa N, Sato Y, Kondo E, Aoe M, et al. Synchronous pulmonary MALT lymphoma and pulmonary adenocarcinoma after metachronous gastric MALT lymphoma and gastric adenocarcinoma. J Thorac Oncol. 2008 Nov;3(11):1362–3.

139. Ichihara E, Kiura K, Takigawa N, Omori M, Aoe M, Tanimoto M, et al. Pseudoprogression of lung cancer after concomitant chemoradiotherapy. Jpn J Clin Oncol. 2008 Feb;38(2):140–2.

140. Hotta K, Kiura K, Takigawa N, Matsuo K, Tabata M, Fujiwara Y, et al. Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia. J Clin Oncol. 2008 Dec 10;26(35):5826–7; author reply 5827.

141. Hotta K, Kiura K, Takigawa N, Fujiwara Y, Tabata M, Ueoka H, et al. Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer. 2008 Nov;62(2):236–41.

142. Fujiwara Y, Kiura K, Toyooka S, Hotta K, Tabata M, Takigawa N, et al. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer. 2008 Jan;59(1):81–7.

143. Fujiwara Y, Kiura K, Tabata M, Takigawa N, Hotta K, Umemura S, et al. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs. 2008 Apr;19(4):431–3.

144. Umemura S, Segawa Y, Ueoka H, Hotta K, Kiura K, Takigawa N, et al. Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer. J Cancer Res Clin Oncol. 2007 Aug;133(8):519–24.

145. Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, et al. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 2007 Mar;98(3):357–63.

146. Teraishi F, Kagawa S, Uno F, Takeda H, Takigawa N, Fujiwara T, et al. [Successfully resected stage IIIA non-small cell lung cancer with mediastinal lymphnode metastasis after chemotherapy of cisplatin and docetaxel combined with concurrent radiation]. Gan To Kagaku Ryoho. 2007 Sep;34(9):1493–5.

147. Takigawa N, Takeyama M, Kozuki T, Shibayama T, Hisamoto A, Kiura K, et al. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. Oncol Rep. 2007 May;17(5):983–7.

148. Takigawa N, Tada A, Soda R, Date H, Yamashita M, Endo S, et al. Distance and oxygen desaturation in 6-min walk test predict prognosis in COPD patients. Respir Med. 2007 Mar;101(3):561–7.

149. Takigawa N, Tada A, Soda R, Takahashi S, Kawata N, Shibayama T, et al. Comprehensive pulmonary rehabilitation according to severity of COPD. Respir Med. 2007 Feb;101(2):326–32.

150. Tabata M, Kozuki T, Ueoka H, Kiura K, Harita S, Tada A, et al. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol. 2007 Jun;60(1):53–9.

151. Osawa M, Takigawa N, Kiura K, Ichimura K, Matsuoka J, Hotta K, et al. Isolated metastasis of lung cancer to the thyroid gland. Lung Cancer. 2007 Oct;58(1):156–8.

152. Ohashi K, Kiura K, Takigawa N, Umemura S, Kondo N, Takemoto M, et al. Radiation necrosis mimicking progressive brain metastasis in a patient with non-small cell lung cancer. J Thorac Oncol. 2007 Aug;2(8):762–3.

153. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007 Aug 15;67(16):7807–14.

154. Kubo T, Takigawa N, Tanimoto Y, Ichihara E, Tabata M, Miyahara N, et al. [Coinfection with Mycoplasma pneumoniae and Chlamydophila pneumoniae in a middle-aged adult]. Nihon Kokyuki Gakkai Zasshi. 2007 Oct;45(10):808–11.

155. Kozuki T, Hisamoto A, Tabata M, Takigawa N, Kiura K, Segawa Y, et al. Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer. 2007 Oct;58(1):30–5.

156. Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, et al. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial. J Thorac Oncol. 2007 Jan;2(1):44–50.

157. Hotta K, Tabata M, Kiura K, Kozuki T, Hisamoto A, Katayama H, et al. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. Oncol Rep. 2007 Feb;17(2):313–7.

158. Hotta K, Kiura K, Toyooka S, Takigawa N, Soh J, Fujiwara Y, et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2007 Jul;2(7):632–7.

159. Hotta K, Kiura K, Tabata M, Takigawa N, Fujiwara Y, Umemura S, et al. Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer. Anticancer Res. 2007 Jun;27(3B):1737–41.

160. Hotta K, Fujiwara Y, Matsuo K, Suzuki T, Kiura K, Tabata M, et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer. 2007 Mar 1;109(5):939–48.

161. Hotta K, Fujiwara Y, Kiura K, Takigawa N, Tabata M, Ueoka H, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol. 2007 May;2(5):402–7.

162. Hisamoto A, Kondo E, Kiura K, Okada T, Hosokawa S, Mimoto J, et al. Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice. Lung Cancer. 2007 Oct;58(1):15–20.

163. Fujiwara Y, Kiura K, Hotta K, Tabata M, Takigawa N, Tanimoto M. Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. Lung Cancer. 2007 Mar;55(3):343–8.

164. Fujii M, Kiura K, Takigawa N, Takeda H, Tanimoto M. Super scan using positron emission tomography in lung cancer patients. J Thorac Oncol. 2007 Nov;2(11):1042–3.

165. Fujii M, Kiura K, Takigawa N, Yumoto T, Sehara Y, Tabata M, et al. Presentation of Garcin syndrome due to lung cancer. J Thorac Oncol. 2007 Sep;2(9):877–8.

166. Takigawa N, Vaziri SAJ, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, et al. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms. Anticancer Res. 2006 Jun;26(3A):1869–76.

167. Takigawa N, Takeyama M, Shibayama T, Tada A, Kawata N, Okada C, et al. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells. Oncol Rep. 2006 Apr;15(4):837–42.

168. Takigawa N, Kiura K, Tabata M, Tanimoto M. Fractionated administration of irinotecan and cisplatin in Japanese patients with extensive-stage-disease small-cell lung cancer. J Clin Oncol. 2006 Nov 10;24(32):5175; author reply 5175-5176.

169. Suzaki N, Hiraki A, Takigawa N, Ueoka H, Tanimoto Y, Kozuki T, et al. Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung. Acta Med Okayama. 2006 Oct;60(5):295–8.

170. Shibayama T, Hotta K, Takigawa N, Tada A, Ueoka H, Harita S, et al. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung Cancer. 2006 Aug;53(2):189–95.

171. Segawa Y, Hotta K, Umemura S, Fujiwara Y, Shinkai T, Ueoka H, et al. Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer. 2006 Oct 15;107(8):1866–72.

172. Ohashi K, Kiura K, Takigawa N, Mizushima T, Ino H, Tabata M, et al. Successful treatment of a patient with gastric and duodenal metastases from large cell carcinoma of the lung with carboplatin and gemcitabine. Anticancer Res. 2006 Dec;26(6C):4695–6.

173. Kawata N, Kawahara S, Tada A, Takigawa N, Shibayama T, Soda R, et al. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM]. Kekkaku. 2006 Apr;81(4):329–35.

174. Harita S, Watanabe Y, Kiura K, Tabata M, Takigawa N, Kuyama S, et al. Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer. Anticancer Res. 2006 Apr;26(2B):1637–41.

175. Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2006 Apr;52(1):99–103.

176. Fujiwara K, Ueoka H, Kiura K, Tabata M, Takigawa N, Hotta K, et al. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2006 Jun;57(6):755–60.

177. Vaziri SAJ, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, et al. Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. Mol Cancer Ther. 2005 Dec;4(12):1880–90.

178. Takigawa N, Takeuchi M, Shibayama T, Yoshida I, Kawata N, Tada A, et al. Successful treatment of a patient with synchronous advanced non-small cell lung cancer and acute myeloid leukemia by a combination of gefitinib, low-dose cytarabine and aclarubicin. Anticancer Res. 2005 Jun;25(3c):2579–82.

179. Takigawa N, Kawata N, Shibayama T, Tada A, Kimura G, Munemasa M, et al. Successful treatment of a patient with severe Churg-Strauss syndrome by a combination of pulse corticosteroids, pulse cyclophosphamide, and high-dose intravenous immunoglobulin. J Asthma. 2005 Oct;42(8):639–41.

180. Matsumura T, Takigawa N, Kiura K, Shibayama T, Chikamori M, Tabata M, et al. Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity. In Vivo. 2005 Aug;19(4):717–21.

181. Hotta K, Takigawa N, Kiura K, Tabata M, Umemura S, Ogino A, et al. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res. 2005 Jun;25(3c):2429–34.

182. Heike Y, Hosokawa M, Osumi S, Fujii D, Aogi K, Takigawa N, et al. Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res. 2005 Apr;25(2B):1197–203.

183. Takigawa N, Shibayama T, Tada A, Kawata N, Kimura G, Hirano A, et al. [Interstitial pneumonia due to gefitinib followed in detail by high-resolution CT in a patient with adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi. 2004 Jun;42(6):523–7.

184. Takigawa N, Segawa Y, Kishino D, Fujiwara K, Tokuda Y, Seki N, et al. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol. 2004 Sep;54(3):230–6.

185. Hirano A, Tada A, Takigawa N, Kawata N, Kimura G, Shibayama T, et al. [Pulmonary tuberculosis case with consistant findings of endobronchial spread in chest roentogenography for about three years: a case report]. Kekkaku. 2004 Aug;79(8):475–9.

186. Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, et al. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res. 2004 Dec;24(6):3911–6.

187. Vaziri SA, Grabowski DR, Tabata M, Holmes KA, Sterk J, Takigawa N, et al. c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis. Anticancer Res. 2003 Oct;23(5A):3657–61.

188. Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, et al. Apoptotic pathways of epothilone BMS 310705. Gynecol Oncol. 2003 Oct;91(1):173–8.

189. Takigawa N, Ida M, Segawa Y, Nakata M, Mandai K, Kishino D, et al. Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia. Anticancer Res. 2003 Dec;23(6D):5069–73.

190. Takigawa N, Fujiwara K, Ueoka H, Kiura K, Tabata M, Hiraki A, et al. Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study. Anticancer Res. 2003 Feb;23(1B):557–60.

191. Segawa Y, Ueoka H, Kiura K, Tabata M, Takigawa N, Hiraki Y, et al. Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer. 2003 Jul;41(1):13–20.

192. Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, et al. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res. 2003 Jun;23(3C):2829–36.

193. Tanaka M, Hiraki A, Ueoka H, Bessho A, Kiura K, Takigawa N, et al. Gingival metastasis in lung cancer. Oncol Rep. 2002 Jun;9(3):571–4.

194. Takigawa N. [Docetaxel]. Nippon Rinsho. 2002 May;60 Suppl 5:349–52.

195. Takata I, Ueoka H, Kiura K, Tabata M, Takigawa N, Katayama H, et al. Daily low-dose cisplatin and concurrent thoracic irradiation for poor-risk patients with unresectable non-small-cell lung cancer. Acta Med Okayama. 2002 Oct;56(5):261–6.

196. Suzaki N, Hiraki A, Ueoka H, Aoe M, Takigawa N, Kishino T, et al. Gastric perforation due to metastasis from adenocarcinoma of the lung. Anticancer Res. 2002 Apr;22(2B):1209–12.

197. Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y, et al. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer. 2002 Jun;36(3):313–9.

198. Kawada K, Yonei T, Ueoka H, Kiura K, Tabata M, Takigawa N, et al. Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. Acta Med Okayama. 2002 Jun;56(3):129–34.

199. Hiraki A, Ueoka H, Bessho A, Segawa Y, Takigawa N, Kiura K, et al. Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer. 2002 Oct 15;95(8):1706–13.

200. Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, et al. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer. 2002 Mar;35(3):329–33.

201. Ganapathi R, Vaziri SAJ, Tabata M, Takigawa N, Grabowski DR, Bukowski RM, et al. Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. Curr Pharm Des. 2002;8(22):1945–58.

業績・論文等

詳細はPC用ページを参照ください。

准教授
小原 弘之

Hiroyuki Kohara

 卒業して初期研修、内科研修を終えてから、呼吸器内科の基礎研究、臨床研究に携わってきました。6年目から呼吸困難の症状緩和治療から緩和医療全般に従事するようになり、終末期のがん疼痛治療、輸液治療、呼吸困難の緩和のガイドライン作成、緩和領域の多施設共同研究などに20年近く関わってきました。今は意思決定支援、アドバンス・ケア・プランニング、がん診断時からの緩和ケア、非がんの心不全やHIVの緩和ケアなどに取り組んでいます。
 また総合診療を通じて、地域で必要とされる救急医療やプライマリーケアを学ぶ機会を頂き、これらを通じて質の高い地域医療の発展に貢献したいと考えています。

准教授
小原 弘之

Hiroyuki Kohara

 卒業して初期研修、内科研修を終えてから、呼吸器内科の基礎研究、臨床研究に携わってきました。6年目から呼吸困難の症状緩和治療から緩和医療全般に従事するようになり、終末期のがん疼痛治療、輸液治療、呼吸困難の緩和のガイドライン作成、緩和領域の多施設共同研究などに20年近く関わってきました。今は意思決定支援、アドバンス・ケア・プランニング、がん診断時からの緩和ケア、非がんの心不全やHIVの緩和ケアなどに取り組んでいます。
 また総合診療を通じて、地域で必要とされる救急医療やプライマリーケアを学ぶ機会を頂き、これらを通じて質の高い地域医療の発展に貢献したいと考えています。

略歴

H3 山口大学卒

所属学会

日本内科学会・日本呼吸器学会・日本緩和医療学会

専門分野

がん疼痛緩和/呼吸困難/消化器症状他の緩和支持療法/輸液治療

資格等

日本内科学会 内科認定医
日本内科学会 総合内科専門医・指導医
日本緩和医療学会 緩和医療専門医
日本呼吸器学会 呼吸器専門医

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.
1. Odagiri T, Morita T, Sakurai H, Yamada H, Matsuo N, Matsumoto Y, et al. A Multicenter Cohort Study to Explore Differentiating Factors between Tumor Fever and Infection among Advanced Cancer Patients. J Palliat Med. 2019 Nov;22(11):1331–6.

2. Hisanaga T, Shinjo T, Imai K, Katayama K, Kaneishi K, Honma H, et al. Clinical Guidelines for Management of Gastrointestinal Symptoms in Cancer Patients: The Japanese Society of Palliative Medicine Recommendations. J Palliat Med. 2019 Aug;22(8):986–97.

None
1. Mori M, Shirado AN, Morita T, Okamoto K, Matsuda Y, Matsumoto Y, et al. Predictors of response to corticosteroids for dyspnea in advanced cancer patients: a preliminary multicenter prospective observational study. Support Care Cancer. 2017;25(4):1169–81.

2. Matsuo N, Morita T, Matsuda Y, Okamoto K, Matsumoto Y, Kaneishi K, et al. Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study. Support Care Cancer. 2017;25(1):41–50.

3. Matsuo N, Morita T, Matsuda Y, Okamoto K, Matsumoto Y, Kaneishi K, et al. Predictors of Delirium in Corticosteroid-Treated Patients with Advanced Cancer: An Exploratory, Multicenter, Prospective, Observational Study. J Palliat Med. 2017;20(4):352–9.

4. Yamaguchi T, Goya S, Kohara H, Watanabe H, Mori M, Matsuda Y, et al. Treatment Recommendations for Respiratory Symptoms in Cancer Patients: Clinical Guidelines from the Japanese Society for Palliative Medicine. J Palliat Med. 2016;19(9):925–35.

5. Matsuo N, Morita T, Matsuda Y, Okamoto K, Matsumoto Y, Kaneishi K, et al. Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study. J Pain Symptom Manage. 2016;52(1):64–72.

6. Miyashita M, Wada M, Morita T, Ishida M, Onishi H, Sasaki Y, et al. Independent Validation of the Japanese Version of the EORTC QLQ-C15-PAL for Patients With Advanced Cancer. J Pain Symptom Manage. 2015 May;49(5):953–9.

7. Sasahara T, Watakabe A, Aruga E, Fujimoto K, Higashi K, Hisahara K, et al. Assessment of reasons for referral and activities of hospital palliative care teams using a standard format: a multicenter 1000 case description. J Pain Symptom Manage. 2014 Mar;47(3):579-587.e6.

8. Yamaguchi T, Morita T, Shinjo T, Inoue S, Takigawa C, Aruga E, et al. Effect of parenteral hydration therapy based on the Japanese national clinical guideline on quality of life, discomfort, and symptom intensity in patients with advanced cancer. J Pain Symptom Manage. 2012 Jun;43(6):1001–12.

9. Morita T, Akechi T, Ikenaga M, Inoue S, Kohara H, Matsubara T, et al. Terminal delirium: recommendations from bereaved families’ experiences. J Pain Symptom Manage. 2007 Dec;34(6):579–89.

10. Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, et al. Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage. 2005 Oct;30(4):308–19.

11. Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, et al. Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage. 2005 Oct;30(4):320–8.

12. Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, et al. Late referrals to specialized palliative care service in Japan. J Clin Oncol. 2005 Apr 20;23(12):2637–44.

13. Kohara H, Ueoka H, Takeyama H, Murakami T, Morita T. Sedation for terminally ill patients with cancer with uncontrollable physical distress. J Palliat Med. 2005 Feb;8(1):20–5.

14. Morita T, Ikenaga M, Adachi I, Narabayashi I, Kizawa Y, Honke Y, et al. Family experience with palliative sedation therapy for terminally ill cancer patients. J Pain Symptom Manage. 2004 Dec;28(6):557–65.

15. Morita T, Ikenaga M, Adachi I, Narabayashi I, Kizawa Y, Honke Y, et al. Concerns of family members of patients receiving palliative sedation therapy. Support Care Cancer. 2004 Dec;12(12):885–9.

16. Kohara H, Miyauchi T, Suehiro Y, Ueoka H, Takeyama H, Morita T. Combined modality treatment of aromatherapy, footsoak, and reflexology relieves fatigue in patients with cancer. J Palliat Med. 2004 Dec;7(6):791–6.

17. Aoe K, Kiura K, Ueoka H, Tabata M, Chikamori M, Kohara H, et al. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. Anticancer Res. 2004 Dec;24(6):3893–7.

業績・論文等

詳細はPC用ページを参照ください。

准教授
山根 弘路

Hiromichi Yamane

卒業以来、約20年間、腫瘍内科医として医療に携わらせていただきました。患者さんの傍に寄り添うことの出来る医療を心がけ、また患者さんにとって最良の選択が出来ることを目標として、診療に取り組みたいと考えています。 また前任地で外来化学療法やがん登録などがん診療の基本的な体制整備や血液疾患診療、緩和ケアなどに携わっていた経験があり、出来れば当院においても同様に、地域の皆様のお役に立ちたいと考えております。よろしくお願い申し上げます。

准教授
山根 弘路

Hiromichi Yamane

卒業以来、約20年間、腫瘍内科医として医療に携わらせていただきました。患者さんの傍に寄り添うことの出来る医療を心がけ、また患者さんにとって最良の選択が出来ることを目標として、診療に取り組みたいと考えています。 また前任地で外来化学療法やがん登録などがん診療の基本的な体制整備や血液疾患診療、緩和ケアなどに携わっていた経験があり、出来れば当院においても同様に、地域の皆様のお役に立ちたいと考えております。よろしくお願い申し上げます。

略歴

H5 岡山大学卒

所属学会

日本内科学会、日本癌学会、日本癌治療学会、日本肺癌学会、日本呼吸器学会、日本臨床腫瘍学会、米国癌学会、日本緩和医療学会

専門分野

腫瘍全般・呼吸器疾患・消化器・血液腫瘍

資格等

日本内科学会認定医
日本内科学会 総合内科専門医・指導医
日本消化器内視鏡学会 専門医・指導医
日本癌治療認定機構 がん治療認定医・暫定教育医
日本消化器病学会専門医・指導医
日本緩和医療学会 緩和医療専門医
日本血液学会 専門医・指導医

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.
1. Kawahara T, Ochi N, Kato K, Shibamoto K, Nagasaki Y, Nakagawa N, et al. Wandering consolidation. Thorax. 2019 Aug;74(8):821–2.
1. Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, et al. Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17. Ther Clin Risk Manag. 2018;14:1457–65.

2. Yamane H, Nishie H, Ochi N, Yamagishi T, Nakagawa N, Nagasaki Y, et al. “Engagement ring” image conveys regrettable outcome for aged patients with non-small cell lung cancer. Thorac Cancer. 2018;9(7):897–8.

3. Yamane H, Kunisada T, Ozaki T, Ochi N, Honda Y, Nagasaki Y, et al. Patients with osteosarcoma and soft tissue sarcoma might become “cancer refugees” in some Japanese regional cities. Cancer Manag Res. 2018;10:353–9.

4. Takigawa N, Ochi N, Yamane H. Histology versus cytology: PD-L1 testing in non-small cell lung cancer. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S225–7.

5. Takigawa N, Ochi N, Yamane H. Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S352–5.

6. Ochi N, Yamane H, Honda Y, Takigawa N. Accidental aspiration of denture cleanser tablets caused severe mucosal edema in upper airway. Clin Respir J. 2018 Jan;12(1):291–4.

7. Ochi N, Wakabayashi T, Urakami A, Yamatsuji T, Ikemoto N, Nagasaki Y, et al. Descending necrotizing mediastinitis in a healthy young adult. Ther Clin Risk Manag. 2018;14:2013–7.

8. Ochi N, Takahashi K, Yamane H, Takigawa N. Acute necrotizing encephalopathy in an adult with influenza A infection. Ther Clin Risk Manag. 2018;14:753–6.

9. Ochi N, Kawahara T, Yamane H, Takigawa N. Erythema as a Visual Surrogate Marker of Glucagonoma. Intern Med. 2018 Aug 1;57(15):2283–4.

10. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018 Nov 1;48(11):995–1000.

11. Nakagawa N, Ochi N, Yamane H, Honda Y, Nagasaki Y, Urata N, et al. Ceftriaxone-associated pancreatitis captured on serial computed tomography scans. Radiol Case Rep. 2018 Feb;13(1):43–6.

1. Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097–103.

2. Honda Y, Takigawa N, Ichihara E, Ninomiya T, Kubo T, Ochi N, et al. Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells. Acta Med Okayama. 2017;71(6):505–12.

3. Yamane H, Ochi N, Honda Y, Takigawa N. Gynecomastia as a Paraneoplastic Symptom of Choriocarcinoma. Intern Med. 2016;55(18):2739–40.

4. Yamane H, Monobe Y, Tanikawa T, Ochi N, Honda Y, Kawamoto H, et al. Herpetic esophagitis following bendamustine-containing regimen. Ther Clin Risk Manag. 2016;12:883–6.

5. Ochi N, Yamane H, Honda Y, Takigawa N. Dropped Head Syndrome Following Mantle Radiation Therapy. Intern Med. 2016;55(4):421–2.

6. Ochi N, Isozaki H, Takeyama M, Singer JW, Yamane H, Honda Y, et al. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. Exp Cell Res. 2016 10;344(2):194–200.

7. Nagasaki Y, Yamane H, Ochi N, Honda Y, Takigawa N. High Uptake of FDG Along a Biliary Stent. Clin Nucl Med. 2016 Nov;41(11):890–1.

8. Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, et al. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Res. 2016 Mar 15;76(6):1506–16.

9. Yamane H, Ochi N, Yamagishi T, Takigawa N, Maeda Y. Progressive paraplegia caused by recurrence of mantle-cell lymphoma with atypical spinal magnetic resonance imaging features. J Cancer Res Ther. 2015 Dec;11(4):1036.

10. Yamane H, Ochi N, Yamagishi T, Honda Y, Takeyama M, Takigawa N. Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study. Ther Clin Risk Manag. 2015;11:949–59.

11. Yamane H, Ochi N, Honda Y, Takigawa N. PET Superscan Caused by Lung Cancer. Intern Med. 2015;54(22):2951.

12. Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, et al. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Am J Cancer Res. 2015;5(4):1553–7.

13. Yamane H, Fukuda N, Nishino K, Yoshida K, Ochi N, Yamagishi T, et al. Non-occlusive mesenteric ischemia after splenic metastasectomy for small-cell lung cancer. Intern Med. 2015;54(7):743–7.

14. Yamagishi T, Ochi N, Yamane H, Kuribayashi F, Takigawa N. A 60-year-old asymptomatic woman with pulmonary lesions and cervical lymphadenopathy. Chest. 2015 Feb;147(2):e48–51.

15. Isoda R, Yamane H, Nezuo S, Monobe Y, Ochi N, Honda Y, et al. Successful palliation for an aged patient with primary pericardial mesothelioma. World J Surg Oncol. 2015 Sep 17;13:273.

16. Yamane H, Ochi N, Yamagishi T, Takigawa N. Guidelines for long-term steroid therapy in end-of-life palliative care. J Clin Oncol. 2014 Feb 20;32(6):607–8.

17. Yamane H, Ochi N, Yamagishi T, Takigawa N. Fibrin sheath following pleurodesis. BMJ Case Rep. 2014 Jan 31;2014.

18. Yamane H, Ochi N, Isozaki H, Yamagishi T, Honda Y, Takigawa N. Skin involvement in diffuse large B-cell lymphoma detected using positron emission tomography. Thorac Cancer. 2014 Nov;5(6):581–2.

19. Yamagishi T, Shimizu K, Ochi N, Yamane H, Irei I, Sadahira Y, et al. Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between “squamous” and “non-squamous” cell carcinoma. Diagn Pathol. 2014 May 29;9:103.

20. Yamagishi T, Ochi N, Yamane H, Takigawa N. Neurogenic pulmonary edema after subarachnoid hemorrhage. J Emerg Med. 2014 May;46(5):683–4.

21. Yamagishi T, Ochi N, Yamane H, Hasebe S, Takigawa N. Epiphora in lung cancer patients receiving docetaxel: a case series. BMC Res Notes. 2014 May 30;7:322.

22. Ochi N, Yamane H, Hotta K, Fujii H, Isozaki H, Honda Y, et al. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Drug Des Devel Ther. 2014;8:2401–8.

23. Ochi N, Goto D, Yamane H, Yamagishi T, Honda Y, Monobe Y, et al. Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma. Onco Targets Ther. 2014;7:1847–50.

24. Yamane H, Takigawa N. Thickened colon wall in follicular lymphoma. Int J Hematol. 2013 May;97(5):549–50.

25. Yamane H, Ochi N, Yasugi M, Tabayashi T, Yamagishi T, Monobe Y, et al. Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. Onco Targets Ther. 2013;6:155–60.

26. Ochi N, Yamane H, Yamagishi T, Monobe Y, Takigawa N. Methotrexate-induced lymphoproliferative disease: Epstein-Barr virus-associated lymphomatoid granulomatosis. J Clin Oncol. 2013 Jul 10;31(20):e348-350.

27. Ochi N, Yamane H, Yamagishi T, Takigawa N. Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases. Lung Cancer. 2013 Apr;80(1):111–3.

28. Ochi N, Yamane H, Yamagishi T, Takigawa N, Monobe Y. Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene? Lung Cancer. 2013 Jan;79(1):94–5.

29. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, et al. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Sci. 2013 Jan;104(1):78–84.

30. Yamane H, Ohashi K, Suwaki T, Takigawa N. Ruptured littoral cell angiosarcoma causing hemoperitoneum. Intern Med. 2012;51(3):337–8.

31. Yamane H, Ochi N, Tabayashi T, Takigawa N. Stewart-Treves syndrome after cervical cancer. Intern Med. 2012;51(5):513.

32. Yamane H, Ochi N, Tabayashi T, Lu L, Yamagishi T, Monobe Y, et al. Elevated coagulation factor VIII plasma activity in a patient with lymphangiosarcoma. Intern Med. 2012;51(22):3213–5.

33. Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer. 2012 Jul;77(1):134–9.

34. Tsuchida T, Yamane H, Ochi N, Tabayashi T, Hiraki A, Nogami N, et al. Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancer. Anticancer Res. 2012 Mar;32(3):887–92.

35. Shiote Y, Yamane H, Ninomiya T, Kamei H. Hyaline vascular type Castleman’s disease of the mesentery. Intern Med. 2012;51(17):2489–90.

36. Ochi N, Yasugi M, Yamane H, Tabayashi T, Kawanaka N, Okimoto N, et al. Spontaneous expectoration of tumor tissue in a patient with adenocarcinoma of the lung. Respir Care. 2012 Sep;57(9):1521–3.

37. Yamane H, Shiote Y, Harada D, Kamei H. Ovarian inguinal hernia in an elderly female. Intern Med. 2011;50(21):2709.

38. Yamane H, Ohsawa M, Shiote Y, Umemura S, Suwaki T, Shirakawa A, et al. Cavitary pulmonary involvement of diffuse large B-cell lymphoma transformed from extra nodal marginal zone B-cell lymphoma MALT type. Clin J Gastroenterol. 2011 Dec;4(6):401–6.

39. Yamane H, Matsubara M, Umemura S, Suwaki T, Kamei H, Takigawa N, et al. Variant angina pectoris associated with FOLFOX4 therapy. World J Gastrointest Oncol. 2011 Nov 15;3(11):165–8.

40. Yamane H, Kinugawa M, Umemura S, Shiote Y, Kudo K, Suwaki T, et al. An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. World J Clin Oncol. 2011 Jul 10;2(7):299–302.

41. Umemura S, Yamane H, Yano T, Hoshika T, Shiote Y, Takigawa N, et al. Synchronous double primary lung cancers with different response to pemetrexed. Anticancer Drugs. 2011 Jun;22(5):473–6.

42. Umemura S, Yamane H, Suwaki T, Katoh T, Yano T, Shiote Y, et al. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin Oncol. 2011 Oct;137(10):1469–75.

43. Yano T, Yamane H, Fukuoka R, Ninomiya T, Umemura S, Suzuki S, et al. [Evaluation of efficacy and safety of adjuvant analgesics for peripheral neuropathy induced by cancer chemotherapy in digestive cancer patients-a pilot study]. Gan To Kagaku Ryoho. 2009 Jan;36(1):83–7.

44. Umemura S, Kudo K, Ninomiya T, Shiote Y, Yamane H, Suwaki T, et al. Centrally located squamous cell carcinoma of the lung mimicking endobronchial tuberculosis. J Thorac Oncol. 2009 Sep;4(9):1178–9.

45. Suzuki S, Hirasaki S, Yumoto E, Yamane H, Matsumoto E, Matsumura S, et al. [A case of liposarcoma of the ascending colon mesenterium]. Nihon Shokakibyo Gakkai Zasshi. 2009 Sep;106(9):1343–50.

46. Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, et al. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. Int J Hematol. 2009 Apr;89(3):326–31.

47. Suzuki S, Hirasaki S, Ikeda F, Yumoto E, Yamane H, Matsubara M. Three cases of Solitary Peutz-Jeghers-type hamartomatous polyp in the duodenum. World J Gastroenterol. 2008 Feb 14;14(6):944–7.

48. Hirasaki S, Fujita K, Matsubara M, Kanzaki H, Yamane H, Okuda M, et al. A ruptured large extraluminal ileal gastrointestinal stromal tumor causing hemoperitoneum. World J Gastroenterol. 2008 May 14;14(18):2928–31.

49. Suzuki S, Hirasaki S, Yumoto E, Yamane H, Taniguchi H, Ikeda F, et al. [A case of early extrahepatic bile duct cancer showing diffuse growth]. Nihon Shokakibyo Gakkai Zasshi. 2007 May;104(5):703–8.

50. Hiraki A, Fujii N, Murakami T, Kiura K, Aoe K, Yamane H, et al. High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines. Anticancer Res. 2004 Jun;24(3a):1525–8.

51. Hisamoto A, Yamane H, Hiraki A, Maeda Y, Fujii N, Sasaki K, et al. Human herpes virus-8-negative primary effusion lymphoma in a patient with common variable immunodeficiency. Leuk Lymphoma. 2003 Nov;44(11):2019–22.

52. Arao T, Ishida E, Nishina S, Yamane H, Adachi M, Sunayama T, et al. Catastrophic intraabdominal bleeding due to rupture of pancreaticoduodenal artery aneurysm: successful transcatheter arterial embolization. Pancreas. 2003 Jan;26(1):99–100.

53. Tada A, Ueoka H, Kiura K, Tabata M, Takemoto M, Yamane H, et al. [Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer]. Gan To Kagaku Ryoho. 2002 May;29(5):751–6.

54. Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, et al. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer. 2002 Mar;35(3):329–33.

業績・論文等

詳細はPC用ページを参照ください。

准教授
中西 秀和

Hidekazu Nakanishi

平成29年3月まで川崎医科大学附属病院において19年間血液内科医として診療に従事してまいりました。当院においても地域の皆様のお役に立てるよう力を尽くしていきたいと思いますので、よろしくお願いいたします。

准教授
中西 秀和

Hidekazu Nakanishi

平成29年3月まで川崎医科大学附属病院において19年間血液内科医として診療に従事してまいりました。当院においても地域の皆様のお役に立てるよう力を尽くしていきたいと思いますので、よろしくお願いいたします。

略歴

H7 川崎医科大学卒

所属学会

日本内科学会、日本血液学会

専門分野

内科一般、血液・腫瘍

資格等

日本内科学会認定内科医・総合内科専門医・指導医
日本血液学会認定血液専門医

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.

1. Kawahara T, Ochi N, Kato K, Shibamoto K, Nagasaki Y, Nakagawa N, et al. Wandering consolidation. Thorax. 2019 Aug;74(8):821–2.

2. Hirose T, Tokunaga H, Shimizu-Koresawa R, Yamada S, Kondo T, Suetsugu Y, et al. [Relationship between Coombs-positive autoimmune hemolytic anemia and development of malignant tumors: a retrospective study]. Rinsho Ketsueki. 2019;60(10):1418–24.

1. Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, et al. Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17. Ther Clin Risk Manag. 2018;14:1457–65.

2. Yamane H, Nishie H, Ochi N, Yamagishi T, Nakagawa N, Nagasaki Y, et al. “Engagement ring” image conveys regrettable outcome for aged patients with non-small cell lung cancer. Thorac Cancer. 2018;9(7):897–8.

3. Yamane H, Kunisada T, Ozaki T, Ochi N, Honda Y, Nagasaki Y, et al. Patients with osteosarcoma and soft tissue sarcoma might become “cancer refugees” in some Japanese regional cities. Cancer Manag Res. 2018;10:353–9.

4. Ochi N, Wakabayashi T, Urakami A, Yamatsuji T, Ikemoto N, Nagasaki Y, et al. Descending necrotizing mediastinitis in a healthy young adult. Ther Clin Risk Manag. 2018;14:2013–7.

5. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018 Nov 1;48(11):995–1000.

6. Nakagawa N, Ochi N, Yamane H, Honda Y, Nagasaki Y, Urata N, et al. Ceftriaxone-associated pancreatitis captured on serial computed tomography scans. Radiol Case Rep. 2018 Feb;13(1):43–6.

1. Kondo T, Tasaka T, Tomioka N, Sano F, Tokunaga H, Suemori S-I, et al. Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms. Springerplus. 2016;5(1):1146.

2. Fuminori Sano null, Toshinori Kondo null, Seiko Susuki null, Hayashi K, Hyo R, Takeuchi A, et al. [Case Report ; Levocarnitine supplementation has been ameliorated prolonged cytopenia of the patient after chemoradiotherapy]. Nippon Naika Gakkai Zasshi. 2016 Dec;105(12):2409–16.

3. Wada H, Suemori S-I, Nakanishi H, Sugihara T. [Band 3 deficiency as a cause of hereditary spherocytosis]. Rinsho Ketsueki. 2015 Jul;56(7):837–45.

4. Suemori S, Wada H, Nakanishi H, Tsujioka T, Sugihara T, Tohyama K. Analysis of Hereditary Elliptocytosis with Decreased Binding of Eosin-5-maleimide to Red Blood Cells. Biomed Res Int. 2015;2015:451861.

5. Nakanishi H, Wada H, Suemori S, Sugihara T. [Hereditary red cell membrane disorders in Japan: comparison with other countries]. Rinsho Ketsueki. 2015 Jul;56(7):760–70.

6. Kondo T, Tasaka T, Matsumoto K, Matsumoto R, Koresawa L, Sano F, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia with extramedullary and meningeal relapse after allogeneic hematopoietic stem cell transplantation that was successfully treated with dasatinib. Springerplus. 2014;3:177.

7. Wada H, Tanabe S, Ichikawa K, Sano F, Kubo Y, Matsuhashi Y, et al. [Development of treatment adherence by jellification of itraconazole oral solution]. Jpn J Antibiot. 2009 Feb;62(1):17–25.

8. Kondo T, Tasaka T, Sano F, Matsuda K, Kubo Y, Matsuhashi Y, et al. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts. Leuk Res. 2009 Sep;33(9):e137-138.

9. Tsujioka T, Wada H, Yata K, Kondo T, Suemori S, Tokunaga H, et al. [Clinical analysis of eight patients with primary follicular lymphoma in the duodenum]. Rinsho Ketsueki. 2007 Feb;48(2):134–9.

10. Remus R, Kanzaki A, Yawata A, Wada H, Nakanishi H, Sugihara T, et al. Relationships between DNA methylation and expression in erythrocyte membrane protein (band 3, protein 4.2, and beta-spectrin) genes during human erythroid development and differentiation. Int J Hematol. 2005 Dec;82(5):422–9.

11. Remus R, Kanzaki A, Yawata A, Nakanishi H, Wada H, Sugihara T, et al. DNA methylation in promoter regions of red cell membrane protein genes in healthy individuals and patients with hereditary membrane disorders. Int J Hematol. 2005 Jun;81(5):385–95.

12. Matsumoto H, Koga H, Honda K, Sadahira Y, Suetugu Y, Mikami M, et al. Characterization of secondary GI lesions with anaplastic large-cell (Ki-1) lymphoma: a first report of two cases. Gastrointest Endosc. 2005 Apr;61(4):607–9.

13. Wada H, Yata K, Mikami M, Suemori S, Nakanishi H, Kondo T, et al. Multiple myeloma complicated by autoimmune hemolytic anemia. Intern Med. 2004 Jul;43(7):595–8.

14. Tsujioka T, Wada H, Yamamori S, Otsuki T, Suemori S, Kondo T, et al. MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia. Int J Hematol. 2003 Dec;78(5):439–42.

15. Yata K, Yamada O, Iwato K, Kyo T, Otsuki T, Nakanishi H, et al. [Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy]. Rinsho Ketsueki. 2002 Jan;43(1):41–3.

16. Kondo T, Wada H, Yata K, Mikami M, Tsujioka T, Suemori S, et al. [Seven patients with stage I and II primary testicular lymphoma]. Rinsho Ketsueki. 2002 Jun;43(6):473–6.

業績・論文等

詳細はPC用ページを参照ください。

講師
越智 宣昭

Nobuaki Ochi

患者さんやご家族の立場に立った診療を心がけています。よろしくお願いします。

講師
越智 宣昭

Tatsuyuki Kawahara

患者さんやご家族の立場に立った診療を心がけています。よろしくお願いします。

略歴

H15 岡山大学卒

所属学会

日本内科学会、日本癌学会、日本癌治療学会、日本肺癌学会、日本呼吸器学会、日本呼吸器内視鏡学会、日本臨床腫瘍学会

専門分野

専門分野 腫瘍全般・呼吸器疾患

資格等

日本内科学会認定医
日本内科学会 総合内科専門医
日本呼吸器学会 専門医
日本癌治療認定機構認定がん治療認定医
日本臨床腫瘍学会 がん薬物療法専門医・指導医
日本呼吸器内視鏡学会 気管支鏡専門医

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.

2. Ichihara E, Harada D, Inoue K, Sato K, Hosokawa S, Kishino D, et al. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer. 2020 Jan;139:140–5.

1. Yin Y, Ochi N, Craven TW, Baker D, Takigawa N, Suga H. De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor. J Am Chem Soc. 2019 Dec 11;141(49):19193–7.

2. Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, et al. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol. 2019 Aug 1;49(8):762–5.

3. Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, et al. Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. Clin Lung Cancer. 2019;20(2):134–8.

4. Kawahara T, Ochi N, Kato K, Shibamoto K, Nagasaki Y, Nakagawa N, et al. Wandering consolidation. Thorax. 2019 Aug;74(8):821–2.

1. Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, et al. Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17. Ther Clin Risk Manag. 2018;14:1457–65.

2. Yamane H, Nishie H, Ochi N, Yamagishi T, Nakagawa N, Nagasaki Y, et al. “Engagement ring” image conveys regrettable outcome for aged patients with non-small cell lung cancer. Thorac Cancer. 2018;9(7):897–8.

3. Yamane H, Kunisada T, Ozaki T, Ochi N, Honda Y, Nagasaki Y, et al. Patients with osteosarcoma and soft tissue sarcoma might become “cancer refugees” in some Japanese regional cities. Cancer Manag Res. 2018;10:353–9.

4. Takigawa N, Ochi N, Yamane H. Histology versus cytology: PD-L1 testing in non-small cell lung cancer. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S225–7.

5. Takigawa N, Ochi N, Yamane H. Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S352–5.

6. Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, et al. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemother Pharmacol. 2018;82(6):1031–8.

7. Ochi N, Yamane H, Honda Y, Takigawa N. Accidental aspiration of denture cleanser tablets caused severe mucosal edema in upper airway. Clin Respir J. 2018 Jan;12(1):291–4.

8. Ochi N, Wakabayashi T, Urakami A, Yamatsuji T, Ikemoto N, Nagasaki Y, et al. Descending necrotizing mediastinitis in a healthy young adult. Ther Clin Risk Manag. 2018;14:2013–7.

9. Ochi N, Takahashi K, Yamane H, Takigawa N. Acute necrotizing encephalopathy in an adult with influenza A infection. Ther Clin Risk Manag. 2018;14:753–6.

10. Ochi N, Kawahara T, Yamane H, Takigawa N. Erythema as a Visual Surrogate Marker of Glucagonoma. Intern Med. 2018 Aug 1;57(15):2283–4.

11. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018 Nov 1;48(11):995–1000.

12. Nakagawa N, Ochi N, Yamane H, Honda Y, Nagasaki Y, Urata N, et al. Ceftriaxone-associated pancreatitis captured on serial computed tomography scans. Radiol Case Rep. 2018 Feb;13(1):43–6.

1. Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, et al. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer. 2017;112:188–94.

2. Honda Y, Takigawa N, Ichihara E, Ninomiya T, Kubo T, Ochi N, et al. Effects of (-)-epigallocatechin-3-gallate on EGFR- or Fusion Gene-driven Lung Cancer Cells. Acta Med Okayama. 2017;71(6):505–12.

3. Yamane H, Ochi N, Honda Y, Takigawa N. Gynecomastia as a Paraneoplastic Symptom of Choriocarcinoma. Intern Med. 2016;55(18):2739–40.

4. Yamane H, Monobe Y, Tanikawa T, Ochi N, Honda Y, Kawamoto H, et al. Herpetic esophagitis following bendamustine-containing regimen. Ther Clin Risk Manag. 2016;12:883–6.

5. Ochi N, Yamane H, Honda Y, Takigawa N. Dropped Head Syndrome Following Mantle Radiation Therapy. Intern Med. 2016;55(4):421–2.

6. Ochi N, Kawamoto H, Monobe Y, Takigawa N. Cytomegalovirus Colitis in a Lung Cancer Patient. Intern Med. 2016;55(16):2313–4.

7. Ochi N, Isozaki H, Takeyama M, Singer JW, Yamane H, Honda Y, et al. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. Exp Cell Res. 2016 10;344(2):194–200.

8. Nagasaki Y, Yamane H, Ochi N, Honda Y, Takigawa N. High Uptake of FDG Along a Biliary Stent. Clin Nucl Med. 2016 Nov;41(11):890–1.

9. Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, et al. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Res. 2016 Mar 15;76(6):1506–16.

10. Yamane H, Ochi N, Yamagishi T, Takigawa N, Maeda Y. Progressive paraplegia caused by recurrence of mantle-cell lymphoma with atypical spinal magnetic resonance imaging features. J Cancer Res Ther. 2015 Dec;11(4):1036.

11. Yamane H, Ochi N, Yamagishi T, Honda Y, Takeyama M, Takigawa N. Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study. Ther Clin Risk Manag. 2015;11:949–59.

12. Yamane H, Ochi N, Honda Y, Takigawa N. PET Superscan Caused by Lung Cancer. Intern Med. 2015;54(22):2951.

13. Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, et al. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Am J Cancer Res. 2015;5(4):1553–7.

14. Yamane H, Fukuda N, Nishino K, Yoshida K, Ochi N, Yamagishi T, et al. Non-occlusive mesenteric ischemia after splenic metastasectomy for small-cell lung cancer. Intern Med. 2015;54(7):743–7.

15. Yamagishi T, Ochi N, Yamane H, Kuribayashi F, Takigawa N. A 60-year-old asymptomatic woman with pulmonary lesions and cervical lymphadenopathy. Chest. 2015 Feb;147(2):e48–51.

16. Minami D, Takigawa N, Kato Y, Kudo K, Isozaki H, Hashida S, et al. Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. Cancer Sci. 2015 Oct;106(10):1296–302.

17. Isoda R, Yamane H, Nezuo S, Monobe Y, Ochi N, Honda Y, et al. Successful palliation for an aged patient with primary pericardial mesothelioma. World J Surg Oncol. 2015 Sep 17;13:273.

18. Yasugi M, Takigawa N, Ochi N, Ohashi K, Harada D, Ninomiya T, et al. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. Exp Cell Res. 2014 Aug 15;326(2):201–9.

19. Yamane H, Ochi N, Yamagishi T, Takigawa N. Guidelines for long-term steroid therapy in end-of-life palliative care. J Clin Oncol. 2014 Feb 20;32(6):607–8.

20. Yamane H, Ochi N, Yamagishi T, Takigawa N. Fibrin sheath following pleurodesis. BMJ Case Rep. 2014 Jan 31;2014.

21. Yamane H, Ochi N, Isozaki H, Yamagishi T, Honda Y, Takigawa N. Skin involvement in diffuse large B-cell lymphoma detected using positron emission tomography. Thorac Cancer. 2014 Nov;5(6):581–2.

22. Yamagishi T, Shimizu K, Ochi N, Yamane H, Irei I, Sadahira Y, et al. Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between “squamous” and “non-squamous” cell carcinoma. Diagn Pathol. 2014 May 29;9:103.

23. Yamagishi T, Ochi N, Yamane H, Takigawa N. Neurogenic pulmonary edema after subarachnoid hemorrhage. J Emerg Med. 2014 May;46(5):683–4.

24. Yamagishi T, Ochi N, Yamane H, Hasebe S, Takigawa N. Epiphora in lung cancer patients receiving docetaxel: a case series. BMC Res Notes. 2014 May 30;7:322.

25. Ochi N, Yamane H, Hotta K, Fujii H, Isozaki H, Honda Y, et al. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Drug Des Devel Ther. 2014;8:2401–8.

26. Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, Hotta K, et al. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp Cell Res. 2014 Mar 10;322(1):168–77.

27. Ochi N, Goto D, Yamane H, Yamagishi T, Honda Y, Monobe Y, et al. Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma. Onco Targets Ther. 2014;7:1847–50.

28. Murakami T, Takigawa N, Ninomiya T, Ochi N, Yasugi M, Honda Y, et al. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer. 2014 Jan;83(1):30–6.

29. Yamane H, Ochi N, Yasugi M, Tabayashi T, Yamagishi T, Monobe Y, et al. Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation. Onco Targets Ther. 2013;6:155–60.

30. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013 Feb 15;319(4):417–23.

31. Ochi N, Yamane H, Yamagishi T, Monobe Y, Takigawa N. Methotrexate-induced lymphoproliferative disease: Epstein-Barr virus-associated lymphomatoid granulomatosis. J Clin Oncol. 2013 Jul 10;31(20):e348-350.

32. Ochi N, Yamane H, Yamagishi T, Takigawa N. Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases. Lung Cancer. 2013 Apr;80(1):111–3.

33. Ochi N, Yamane H, Yamagishi T, Takigawa N, Monobe Y. Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene? Lung Cancer. 2013 Jan;79(1):94–5.

34. Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013 May;12(5):589–97.

35. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2013 Feb;11(2):140–8.

36. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, et al. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Sci. 2013 Jan;104(1):78–84.

37. Yamane H, Ochi N, Tabayashi T, Takigawa N. Stewart-Treves syndrome after cervical cancer. Intern Med. 2012;51(5):513.

38. Yamane H, Ochi N, Tabayashi T, Lu L, Yamagishi T, Monobe Y, et al. Elevated coagulation factor VIII plasma activity in a patient with lymphangiosarcoma. Intern Med. 2012;51(22):3213–5.

39. Tsuchida T, Yamane H, Ochi N, Tabayashi T, Hiraki A, Nogami N, et al. Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancer. Anticancer Res. 2012 Mar;32(3):887–92.

40. Ochi N, Yasugi M, Yamane H, Tabayashi T, Kawanaka N, Okimoto N, et al. Spontaneous expectoration of tumor tissue in a patient with adenocarcinoma of the lung. Respir Care. 2012 Sep;57(9):1521–3.

41. Ochi N, Yasugi M, Takigawa N. Asymptomatic double aortic arch with compressed oesophagus in an adult. BMJ Case Rep. 2012 Apr 2;2012.

42. Ochi N, Hotta K, Takigawa N, Oze I, Fujiwara Y, Ichihara E, et al. Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. PLoS ONE. 2012;7(8):e42798.

43. Honda Y, Takigawa N, Fushimi S, Ochi N, Kubo T, Ozaki S, et al. Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors. Lung Cancer. 2012 Oct;78(1):121–4.

44. Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, et al. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci. 2012 Oct;103(10):1795–802.

45. Zhang D, Takigawa N, Ochi N, Tanimoto Y, Noujima D, Chen YY, et al. Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung Cancer. 2011 Sep;73(3):379–80.

46. Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, et al. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett. 2011 Oct 28;309(2):228–35.

47. Waseda K, Tanimoto Y, Ichiba S, Miyahara N, Murakami T, Ochi N, et al. Successful extracorporeal life support for life-threatening hypercapnia with bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Acta Med Okayama. 2011 Dec;65(6):403–6.

48. Ochi N, Takigawa N, Yasugi M, Ishida E, Kawamoto H, Taniguchi A, et al. Obstructive jaundice at the initial presentation in small-cell lung cancer. Int Med Case Rep J. 2010;3:9–12.

49. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS ONE. 2009 Nov 13;4(11):e7835.

50. Kubo T, Takigawa N, Kiura K, Nishida A, Ochi N, Kashihara H, et al. Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. Anticancer Res. 2009 Jul;29(7):2759–60.

業績・論文等

詳細はPC用ページを参照ください。

大学院生
中川 望

Nozomu Nakagawa

岡山で腫瘍内科医として成長し、患者さんのためにベストながん治療を提供できるよう、日々努力いたします。

大学院生
中川 望

Nakagawa Nozomu

岡山で腫瘍内科医として成長し、患者さんのためにベストながん治療を提供できるよう、日々努力いたします。

略歴

H25 川崎医科大学卒

所属学会

日本内科学会、日本臨床腫瘍学会、日本肺癌学会、日本呼吸器学会、日本呼吸器内視鏡学会、日本癌学会、日本癌治療学会

専門分野

内科一般、がん薬物療法

資格等

更新中

業績・論文等

更新中です。
更新中です。
更新中です。
竹村 知容(兵庫県立尼崎病院 呼吸器センター), 中川 望, 加耒 佐和子,ら. クリゾチニブ内服中に重度の洞性徐脈を来した92歳のEML4-ALK遺伝子転座陽性例. 日本胸部臨床 74(4), 478-483, 2015-04

竹村 知容(兵庫県立尼崎病院 呼吸器センター), 片岡 裕貴, 中川 望, 加耒 佐和子,ら. 貧血症状で発見された、胃転移を伴う肺小細胞癌の1例. 日本胸部臨床 72(12), 1401-1406, 2013-12.

業績・論文等

詳細はPC用ページを参照ください。

臨床助教
長崎 泰有

Yasunari Nagasaki

患者さんのお役に立てるよう頑張ります。

臨床助教
長崎 泰有

Yasunari Nagasaki

患者さんのお役に立てるよう頑張ります。

略歴

H27 川崎医科大学卒

所属学会

日本内科学会、日本肺癌学会、日本呼吸器学会、日本癌治療学会、日本臨床腫瘍学会、日本呼吸器内視鏡学会、日本緩和医療学会

専門分野

内科一般、呼吸器内科、腫瘍

資格等

日本内科学会 内科認定医

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.
1. Kawahara T, Ochi N, Kato K, Shibamoto K, Nagasaki Y, Nakagawa N, et al. Wandering consolidation. Thorax. 2019 Aug;74(8):821–2.
1. Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, et al. Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17. Ther Clin Risk Manag. 2018;14:1457–65.

2. Yamane H, Nishie H, Ochi N, Yamagishi T, Nakagawa N, Nagasaki Y, et al. “Engagement ring” image conveys regrettable outcome for aged patients with non-small cell lung cancer. Thorac Cancer. 2018;9(7):897–8.

3. Yamane H, Kunisada T, Ozaki T, Ochi N, Honda Y, Nagasaki Y, et al. Patients with osteosarcoma and soft tissue sarcoma might become “cancer refugees” in some Japanese regional cities. Cancer Manag Res. 2018;10:353–9.

4. Ochi N, Wakabayashi T, Urakami A, Yamatsuji T, Ikemoto N, Nagasaki Y, et al. Descending necrotizing mediastinitis in a healthy young adult. Ther Clin Risk Manag. 2018;14:2013–7.

5. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018 Nov 1;48(11):995–1000.

6. Nakagawa N, Ochi N, Yamane H, Honda Y, Nagasaki Y, Urata N, et al. Ceftriaxone-associated pancreatitis captured on serial computed tomography scans. Radiol Case Rep. 2018 Feb;13(1):43–6.

1. Nagasaki Y, Yamane H, Ochi N, Honda Y, Takigawa N. High Uptake of FDG Along a Biliary Stent. Clin Nucl Med. 2016 Nov;41(11):890–1.

業績・論文等

詳細はPC用ページを参照ください。

臨床助教
河原 辰由樹

Tatsuyuki Kawahara

更新中

臨床助教
河原 辰由樹

Tatsuyuki Kawahara

更新中

略歴

H28 川崎医科大学卒

所属学会

日本内科学会

専門分野

内科一般、呼吸器内科、腫瘍

資格等

更新中

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.
1. Kawahara T, Ochi N, Kato K, Shibamoto K, Nagasaki Y, Nakagawa N, et al. Wandering consolidation. Thorax. 2019 Aug;74(8):821–2.
1. Ochi N, Wakabayashi T, Urakami A, Yamatsuji T, Ikemoto N, Nagasaki Y, et al. Descending necrotizing mediastinitis in a healthy young adult. Ther Clin Risk Manag. 2018;14:2013–7.

2. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018 Nov 1;48(11):995–1000.

None

業績・論文等

詳細はPC用ページを参照ください。

臨床助教
田岡 征高

Masataka Taoka

更新中

臨床助教
田岡 征高

Masataka Taoka

更新中

略歴

岡山大学卒

所属学会

日本内科学会、日本呼吸器学会、日本呼吸器内視鏡学会

専門分野

内科一般、呼吸器内科

資格等

更新中

業績・論文等

更新中です。
更新中です。
更新中です。
更新中です。

業績・論文等

詳細はPC用ページを参照ください。

臨床助教
市山 成彦

Naruhiko Ichiyama

更新中

臨床助教
市山 成彦

Naruhiko Ichiyama

更新中

略歴

H29 川崎医科大学卒

所属学会

日本内科学会、日本臨床腫瘍、日本がん治療学会、日本肺癌学会、日本呼吸器学会

専門分野

内科一般

資格等

更新中

業績・論文等

1. Miyake N, Ochi N, Yamane H, Fukazawa T, Ikeda T, Yokota E, et al. Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells. Lung Cancer. 2020 Jan;139:170–8.
None
None
None

業績・論文等

詳細はPC用ページを参照ください。

臨床助教
三村 彩香

Ayaka Mimura

更新中

臨床助教
三村 彩香

Ayaka Mimura

更新中

略歴

H29 川崎医科大学卒

所属学会

更新中

専門分野

内科一般

資格等

更新中

業績・論文等

更新中です。
更新中です。
更新中です。
更新中です。

業績・論文等

詳細はPC用ページを参照ください。

Need more Data Points or Team Members? Please contact us.
Our work

教育

Education

1.学生教育

当教室では、学生教育に特に力を入れています。クリニカル・クラークシップを通して多くの臨床症例を経験し、実際の医療現場での考え方や患者さんへの接し方を学んでもらう一方で、基礎的な考え方をより深く理解してもらうための基礎配属も毎年積極的に受け入れ、実際に手を動かしてデータを出し、解析し、まとめ、発表するという工程を経験してもらうという貴重な経験を積んでもらえるよう指導しています。我々は将来の医療を支えてくれる後進を育てるという大きな目標のために特に力を入れています。

2.研修医教育

当教室では、研修医として日々の診療を通して臨床研修を重ねてもらう傍ら、積極的に個々の症例についての気づきや学びを重視し、研修医の間から積極的に学会発表、論文執筆を行えるようサポートし、指導しています。研修医のうちから症例報告などの論文作成を通して、今後の医学の発展に貢献できるような学術論文を作り上げる知識やノウハウを身につけていけるよう心がけています。


●近年の主な指導論文(研修医、後期研修医分)
Wandaring consolidation.
   Kawahara T, et al. Thorax. 2019 (S2 IF:9.655)
Ceftraxone-associated pancreatitis captured on serial computed tomography scans.
   Nakagawa N, et al. Radiol Case Rep. 2017 (S1)
High Uptake of FDG Along a Biliary Stent.
   Nagasaki Y, et al. Clin Nucl Med. 2016 (J2 IF:6.498)
Successful palliation for an aged patients with primary pericardial mesothelioma.
   Isoda R, et al. World J Surg Oncol. 2015 (J2 IF:1.966)
A 60-year-old asymptomatic woman with pulmonary lesions and cervial lymphadenopathy.
   Yamagishi T, et al. Chest. 2015 (S2 IF:7.132)

研究・業績

Our work

1.研究開始当初の背景

肺癌は喫煙が主たる原因とされるが、日本の肺癌患者は男性の約40%、女性の約80%が非喫煙者となっている。非喫煙者肺腺癌の50-60%に上皮性成長因子受容体(epidermal growth factor receptor: EGFR)遺伝子変異が認められている。この遺伝子は発癌とその進展に関与しており、それらに対してゲフィチニブなどのEGFRチロシンキナーゼ阻害剤(TKI)の有用性が示されてきた。しかしながら、その奏効期間は平均約1年で耐性となるため新たな治療法の開発が望まれている。我々は、EGFR遺伝子改変マウスを開発し、その進展にはEGFR下流のJAK2/STAT3やAKT/mTOR経路の活性化、および血管新生が関与していることを報告してきた。

2.研究の目的

活性型EGFR遺伝子変異肺癌細胞株、異種移植モデル、およびEGFR遺伝子改変マウスにおける、各種分子標的薬剤とシグナル伝達機構を解析し、EGFR-TKI耐性解除を試みる。

3.研究の方法

1) EGFR遺伝子変異細胞株
EGFR-TKIの耐性株は、PC-9(EGFR変異 exon 19欠失)を親株として当科で樹立された4つの耐性株RPC-9(T790M)、PC-9/Van-R(T790M + MET増幅 + HGF増幅)、PC-9/ER3(JAK2/STAT3発現増強)およびPC-9/GR(SRC発現増強)を用いる。薬剤はJAK2/STAT3阻害剤(JSI-124、AZD1480)、EGFRとVEGFRの両阻害剤(バンデタニブ)、第2世代EGFR-TKI(アファチニブ)、SRC阻害剤(ダサチニブ)、mTOR阻害剤(エベロリムス)を使用する。細胞増殖抑制はMTTアッセイで評価する。EGFRシグナル関連蛋白はWestern blottingで検出する。
2) 異種移植モデル
BALB/cAJcl-nu雄5週齢のヌードマウスを2週間予備飼育した後、各腫瘍細胞株を2 x 106個ずつ皮下投与し、異種移植モデルを作製する。約2週間後より腫瘍が確認されるので、腫瘍が0.05cm3になったところで、3群に分け、プラセボ、各種薬剤(低用量と高用量)を投与する。飼育中、腫瘍径の測定を行い、6週間観察する。2週毎に各群2匹ずつsacrificeを行う。組織をホルマリン固定しパラフィン包埋を行い、検体の連続切片を作成しHE染色および免疫組織染色とWestern blottingで蛋白発現を確認する。
3) 遺伝子改変マウス
exon 19欠失とexon 21 L858Rの2系統のEGFR遺伝子改変マウスを用いて、各種薬剤を投与し発癌抑制効果を検討する。マウス3週齢各系統をコントロール群と薬剤投与群とする。1週毎に各群のマウスの体重測定を行い、全身状態を観察する。10週後(15週齢)にsacrificeし、表面から肺腫瘍数と腫瘍サイズを測定する。腫瘍組織はホルマリン固定パラフィン包埋として保存し、EGFR関連蛋白および新生血管の解析を行う。



4.研究成果

1)PC-9/ER3では、非受容型チロシンリン酸化酵素であるJAK2の活性化が認められ、エルロチニブによりリン酸化EGFRは抑制されたものの、EGFR下流シグナルのAKTは不活化されなかった。JAK2阻害剤であるJSI-124とエルロチニブの併用によりPC-9/ER3のJAK2並びにAKTの活性化が抑制され、エルロチニブに対する感受性の回復が得られた(右図上)。

siRNAでJAK2を抑制することでも同様の知見を得た。また、マウスの異種移植モデルを用いてJSI-124とエルロチニブ併用によりPC-9/ER3の有意な腫瘍縮小効果も示した(右図下)。

これらの結果は、JAK2の活性化がエルロチニブの獲得耐性に部分的に関与していることが示唆された。

(Reference)
Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Katsuyuki Kiura, et al. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor activating mutation. Cancer Science 103, 1795-1802, 2012.



2) PTEN欠失のEGFR遺伝子変異を有する肺癌細胞株を用いた異種移植モデルではゲフィチニブと比較してバンデタニブで明らかな腫瘍抑制効果を認めた(図)。EGFR遺伝子変異を有するPTEN欠失肺癌細胞株においてバンデタニブは有用であることが示唆された。

(Reference)
Hiromasa Takeda, Nagio Takigawa, Nobuaki Ochi, Katsuyuki Kiura, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Experimental Cell Research 319, 417-423, 2013.



3)exon 19欠失EGFR遺伝子改変マウスに対して、アファチニブとゲフィチニブをそれぞれ4週間投与したところ、アファチニブ投与群において腫瘍は少ない傾向にあった。病理組織像ではゲフィチニブ投与群で明らかな結節腫瘍の残存が認められた。生存期間を比較したところ、アファチニブはゲフィチニブよりも生存期間を有意に延長した(右図上)。

EGFR-TKI耐性細胞株の異種移植モデルでは、アファチニブとベバシズマブの併用投与は、各単剤投与よりも強い抗腫瘍効果を示した(右図下)。

アファチニブはゲフィチニブよりも有用であり、耐性に対してもベバシズマブとの併用が有用であることが示唆された。

(Reference)
Takashi Ninomiya, Nagio Takigawa, Nobuaki Ochi, Katsuyuki Kiura, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 12:589-597, 2013.



4) AZD1480はゲフィチニブ感受性および耐性細胞株に同等の効果を示した。ゼノグラフトモデルにおいてAZD1480は、血管新生を抑制し腫瘍縮小効果を呈した。遺伝子改変マウスにAZD1480を投与したところ、1 mm以上の肺の腫瘍数(0.37 ± 0.18)は、対照群(2.25 ± 0.53)に比し有意に減少した。さらに、マウスの生存期間中央値も、投与群(217日)が対照群(106日)に比し有意に延長した(図)。AZD1480は、活性型EGFR遺伝子変異を有する肺癌に対して効果が期待できることが示唆された。

(Reference)
Toshi Murakami, Nagio Takigawa, Nobuaki Ochi, Katsuyuki Kiura, et al. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer 83: 30-36. 2014.



5) PC9-GRではゲフィチニブによりEGFRシグナル経路が一旦は抑制されたが、SRCによるERK再活性化が誘導された。ダサチニブとの併用により、PC9-GR はin vitro(図上)でもin vivo(図下)でもゲフィチニブへの感受性が回復した。以上より、SRCを介したERK再活性化が新たなゲフィチニブ獲得耐性機序に関与している可能性が示唆され、ゲフィチニブとSRC阻害剤の併用がこの耐性克服に有効であると考えられた。

(Reference)
Nobuaki Ochi, Nagio Takigawa, Katsuyuki Kiura, et al. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp Cell Res 322: 168-177, 2014.



6) エベロリムスに対する感受性は、EGFR遺伝子変異の有無に関わらずほぼ同等であった。L858R変異を有するEGFR遺伝子改変マウスに5週齢から20週齢までエベロリムスを投与したところ、肺表面の腫瘍数は有意に抑制された。さらにエベロリムスを長期継続投与することにより、有意な生存期間の延長が認められた(図)。エベロリムスはin vitroではアポトーシスとオートファジーを誘導していた。しかしながら、EGFR遺伝子改変マウスにおいてはアポトーシスおよびオートファジーは確認されず、血管新生が抑制されていた。エベロリムスは血管新生を抑制することにより、活性型EGFR遺伝子変異を有する肺癌への有効性が示唆された。

(Reference)
Masayuki Yasugi, Nagio Takigawa, Nobuaki Ochi, Katsuyuki Kiura, et al. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors. Exp Cell Res 326: 201-209, 2014.

研究・業績

Our work

研究・業績についてはPC用ページを参照ください。

For resident

研修医・後期レジデント募集

やる気あふれる研修医、レジデントを随時募集中です。
興味がある方はお気軽にご連絡ください。

Email: info@kawasaki-gim4.main.jp

当科でEvidenceに基づいた臨床腫瘍学を身につけませんか?

当科ではトランスレーショナルリサーチに重点を置いて
基礎から臨床まで幅広い知識を身につけることが出来ます。